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Plasma visfatin has been proposed to act as an insulin-mimetic hormone and to 
enhance glucose uptake.  However, research regarding its insulin-like properties has 
been highly variable.  Furthermore, its response to exercise, carbohydrate ingestion, and 
its overall relationship with blood glucose is not fully understood.  PURPOSE:  To 
examine the effect of high-intensity intermittent exercise and a carbohydrate 
supplementation (CHO) on plasma visfatin.  METHODS: On 2 days separated by at 
least 3 days, 10 sprint-trained male subjects (age = 26.4 ± 5.3 yrs; Ht = 1.77 ± 0.03 m; 
Wt = 78.78 ± 9.10 kg; BF% = 13.96 ± 7.28%) completed 4 bouts of cycling (3 min each), 
at 50% of mean anaerobic power (based on a Wingate Test), with 6 min of rest between 
bouts. On the CHO day, subjects ingested 50g of CHO 30 min prior to exercise.  On the 
control day, subjects ingested a sugar free artificially sweetened drink (CON) 30 min 
prior to exercise.  Blood was drawn prior to supplement ingestion, 15 minutes before 
exercise, before and after each bout of exercise, and 15 and 30 minutes post exercise.  
Plasma visfatin, blood glucose, and plasma insulin were determined.  Body composition 
and truncal fat were also assessed (DXA; Prodigy Advanced, GE Lunar).  RESULTS:  
Visfatin was not significantly different between treatments (CHO vs CON) at any time 
point (p = 0.163), and was not significantly altered by exercise (p = 0.692).  Insulin 
[25.65 vs 8.35 mU/l, CHO vs CON, respecitively] and glucose [138.57 vs 98.10 mg/dl, 
CHO vs CON, respectively] were both elevated after CHO ingestion and remained 
elevated throughout the first half of exercise.  Baseline visfatin was significantly 
correlated with truncal fat (r2 = 0.6162, p < 0.05), but was not correlated with glucose or 
insulin.  CONCLUSION: Although visfatin was correlated to truncal fat in healthy, sprint-
 
 
trained males, it was not altered by high-intensity intermittent exercise or CHO 
supplementation. 
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CHAPTER I 
 
INTRODUCTION 
 
One in 10 Americans suffers from type 2 diabetes mellitus (T2D), which has 
caused annual health care costs to exceed 174 billion dollars (Ong, Cheung et al. 2008).  
T2D is a result of several compounding problems, one of which is decreased sensitivity 
of the insulin receptors both in the periphery and in the pancreas.  This decreased 
peripheral sensitivity is partially due to decreased phosphorylation of certain regulatory 
proteins involved in the cellular signaling pathway (Reaven 1992).  A physiological result 
of this decreased sensitivity of insulin receptors is a decrease in cellular glucose uptake 
and by extension, elevated blood glucose concentrations. Additionally, there is a 
decrease in amino acid uptake if insulin is not working as well.  Exercise has been 
shown to counteract this diabetic chain of events by increasing glucose uptake via 
muscle contraction (independent of insulin) and by increasing insulin action through an 
increase in phosphorylation of certain regulatory proteins of the insulin signaling pathway 
(Hawley and Lessard 2008) which can also influence protein synthesis.   
In 2005, Visfatin was shown to increase glucose uptake independently of insulin 
when administered to mice and in cell cultures of adipose tissue (Fukuhara, Matsuda et 
al. 2005).  The possibility that visfatin may play a role in the regulation of glucose, makes 
it a viable target as a treatment for T2DM.  An inability to regulate blood glucose due to 
decreased insulin action may be attenuated by visfatin.  The extent to which visfatin acts 
on glucose uptake is unknown as are the complexities of its relationship with insulin and 
blood glucose levels.  In order to know more about the effect of visfatin on glucose 
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uptake and metabolism, it is necessary to examine it during conditions of altered blood 
glucose.   
Visfatin was originally discovered as a cytokine that was highly expressed in 
bone marrow, liver, and muscle tissue (Samal, Sun et al. 1994).  It was originally shown 
to facilitate the colonization of B cells. It is important to note that while visfatin has been 
shown to bind to the insulin receptor in one study but not in the same place as insulin 
(Fukuhara, Matsuda et al. 2005), no other receptor interaction has been shown. Its mode 
of action is not currently understood. 
In addition to its proposed metabolic properties, visfatin is elevated in individuals 
who are obese or have T2D (Arner 2006; Dedoussis, Kapiri et al. 2009).  A recent meta-
analysis of the visfatin literature showed that visfatin is elevated in both T2D and type I 
diabetes (Chang, Chang et al. 2011) and visfatin is elevated in obese, non-diabetic, 
hyperglycemic individuals (Tilg and Moschen 2008). In summary, visfatin has been 
shown to have a link to both obesity and diabetes.  
Recently, several studies have shown visfatin to play a role in glucose 
homeostasis. Its specific role is debated, but it has been positively correlated with 
changes in blood glucose and insulin after high-intensity sprint exercise (Ghanbari-Niaki, 
Saghebjoo et al. 2010), as well as enhanced insulin signaling through its action on the 
insulin receptor (Fukuhara, Matsuda et al. 2005; Xie, Tang et al. 2007). Visfatin was first 
discovered as a mediator of glucose homeostasis by Fukuhara (2005).  In this study, 
visfatin administration was shown to improve glucose uptake by influencing insulin 
signaling via the phosphoinositide-3-kinase (PI3K) pathway in obese mice.  While this 
study was retracted shortly after publication for reasons unrelated to these findings, 
other studies have also implicated visfatin as an insulin-mimicking hormone (Xie, Tang 
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et al, Song, Lee at al. 2008).  Improved glucose uptake via visfatin administration has 
also been shown in vitro in human osteoblasts (Xie, Tang et al. 2007) and mesangial 
cells (Song, Lee et al. 2008).  
While the aforementioned studies have focused on the glucose-mediating 
properties of visfatin, several studies have also identified visfatin as a pro-inflammatory 
marker (Romacho, Azcutia et al. 2009; Friebe, Neef et al. 2011).  As previously 
mentioned, visfatin is elevated in obese subjects. Since obesity has been identified as a 
state of chronic low grade inflammation, the elevated plasma visfatin seen with obesity 
may be partially related to chronic inflammation.  In addition, two key inflammatory 
markers (IL-6 and TNF-α) have been shown to directly influence plasma visfatin levels 
and visfatin mRNA within adipose tissue (Frydelund-Larsen, Akerstrom et al. 2007; 
Sheu, Chang et al. 2008).   
There is some debate as to whether visfatin is more strongly correlated to 
visceral adipose tissue or subcutaneous adipose tissue, but visfatin has been shown to 
be strongly correlated with overall body fat (Fukuhara, Matsuda et al. 2005; Chang, 
Chang et al. 2010).  Although visfatin does appear to be released primarily from adipose 
tissue, it has also been shown to be released from liver and muscle tissue (Samal, Sun 
et al. 1994).   
The effects of exercise on visfatin have been varied.  Previous studies have 
shown plasma visfatin levels to be decreased after 45 minutes of moderate intensity 
exercise and these lower levels were correlated with decreases in blood glucose 
(Jurimae, Ramson et al. 2009; Koltai, Szabo et al. 2010; Lee, Shin et al. 2010).  
Conversely, one study has shown an increase in plasma visfatin after high intensity 
sprint exercise (Ghanbari-Niaki, Saghebjoo et al. 2010).  The reason for this disparity in 
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the exercise-induced visfatin response is likely due to differences in exercise intensity, 
subject characteristics, and could also reflect the simultaneous alterations in blood 
glucose and muscle glycogen that coincide with these different exercise intensities.   
High intensity intermittent exercise has been shown to elicit acute increases in 
insulin levels and to increase glucose uptake (MacDougall, Ward et al. 1977). The 
magnitude of these changes is dependent on the intensity of the exercise.  While visfatin 
was shown to be elevated with high intensity sprint exercise, its relationship with 
exercise-induced alterations in blood glucose has only been examined in one study 
(Ghanbari-Niaki, Saghebjoo et al. 2010). They noted elevated glucose and insulin levels 
after sprint exercise (n =6 males) were accompanied by increased plasma visfatin.  
However, there is no research regarding the relationship between visfatin and 
carbohydrate supplementation. In order to fully understand the metabolic role of visfatin, 
it is necessary to determine its response to carbohydrate supplementation.  If visfatin 
does act in a matter similar to insulin, then carbohydrate supplementation should lead to 
an increase in plasma visfatin.  
In a pilot study (unpublished) of the proposed methods for this proposal, 
intermittent exercise performed at 50% of absolute mean power (as determined by a 
Wingate test) for 3-minute intervals after 50g of carbohydrate supplementation using 
cycle ergometry in highly trained subjects (n=2 males), caused a significant decrease in 
blood glucose and plasma visfatin during exercise with a concomitant increase in both 
during a recovery period.  When compared to a control (exercise session without 
carbohydrate supplementation), the change in blood glucose and visfatin was markedly 
less.  Ghanbari-Niaki et al. (2010) reported a similar response using sprint exercise.  
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These data suggest that high intensity exercise followed by an appropriate 
recovery will elevate blood glucose above resting levels during recovery; the main 
source of blood glucose is likely from the liver (MacDougall, Ward et al. 1977). This 
increase in blood glucose is likely used to replenish muscle glycogen after high intensity 
exercise (Costill and Hargreaves 1992).   
 In summary, visfatin has been shown to be elevated in one study after high 
intensity exercise, decreased after low intensity exercise, and elevated in obese 
individuals, and diabetics. Additionally, visfatin is strongly correlated to overall body fat. 
One mechanism for further elucidating the metabolic action(s) of visfatin, is to 
simultaneously investigate the exercise-induced visfatin response and the corresponding 
alterations in blood glucose. 
 
Purpose 
 The primary purpose of this study is to examine the response of plasma visfatin 
to high intensity intermittent exercise and to assess how that response is affected by 
carbohydrate supplementation.  
  
Specific Aims and Hypotheses 
Specific Aim #1:  Determine the response of plasma visfatin to high intensity intermittent 
exercise. 
H1:  High intensity intermittent exercise will increase plasma visfatin.  
Specific Aim #2:  Determine the effect of carbohydrate supplementation on the response 
of visfatin to high intensity exercise. 
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H2: Carbohydrate supplementation will augment the effect of exercise on plasma 
visfatin. 
Specific Aim #3:  Determine if plasma visfatin is correlated to truncal fat in trained young 
males. 
H3:  Plasma visfatin will be positively correlated with truncal fat in trained young males. 
 
Limitations 
1.) One limitation of the current study is that the proposed glucose load is not 
guaranteed to offset the exercise-induced decrease in blood glucose in all 
subjects.  The proposed glucose load is based on recent data from Kraemer and 
colleagues (Kraemer, Francois et al. 2011) which will be discussed in further 
detail in chapter 3.   
2.) All blood draws will be done at an antecubital vein, so blood draws may not be 
completely indicative of what is taking place at the working muscle.  
3.) Conclusions drawn from this study may not be generalizable due to a limited age 
range and the use of highly trained subjects. 
 
Delimitations 
 Subject age (18-30), gender (male), training status (sprint-trained), and health 
(apparently healthy), will all be controlled to limit between-subject variability.   
 
Definition of Terms  
1. Pre-B Cell Colony Enhancing Factor (PBEF) - The original name given to visfatin 
based on its action in the inflammatory process. 
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2. Nicotinamide Phosphoribosyltransferase (NAMPT) - Another term for visfatin 
based on its enzymatic action in the NAD+ salvage pathway. 
3. Visfatin – A possible insulin-mimicking hormone found in body fat, muscle tissue, 
and liver tissue. 
4. Phosphoinositide-3-Kinase (PI3K) – Enzyme with specific actions in the insulin-
signaling pathway to facilitate GLUT4 translocation 
5. Interleukin-6 (IL-6) – Cytokine involved in acute inflammatory phase; also 
released from muscle during exercise. 
6. Insulin Receptor Substrate 1 (IRS1) – Insulin receptor substrate protein with a 
phosphotyrosine binding domain.  Phosphorylation leads to GLUT4 translocation 
7. Glucose Transporter type 4 (GLUT4) – Insulin-regulated protein responsible for 
translocation of glucose into the cell. 
8. Nicotinamide Adenine Dinucleotide (NAD+) – Coenzyme responsible for carrying 
electrons. 
9. Sirtuin Proteins (SIRT) – Proteins with deacetylase or ribosyltransferase activity.   
10. Absolute Mean Power (AMP) – Average power output over 30 seconds during a 
Wingate test. 
11. Adenosine Monophosphate-Activated Kinase (AMPK) – Energy sensing enzyme 
which plays a key role in exercise-induced increases in glucose uptake. 
12. Mesangial Cells – Specialized smooth muscle cells which control renal capillary 
blood flow. 
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CHAPTER II 
REVIEW OF LITERATURE 
Visfatin, NAMPT, and PBEF 
 Visfatin is a 52 kilodalton cytokine which is transcribed in bone marrow, liver, 
muscle, and adipose tissue.  It was originally coined as pre-B-cell colony enhancing 
factor (PBEF) because it was found to synergize the pre-B-cell colony formation activity 
of stem cell factor and interleukin 7 (Samal, Sun et al. 1994).  The 3’ untranslated region 
of visfatin mRNA has multiple TATT motifs which makes it similar to many inflammatory 
cytokine mRNA constructs.  This suggests that the final protein structure of visfatin is 
similar to that of other inflammatory cytokines.  Visfatin has a hydrophobic amino 
terminus with six cysteine residues.  Additionally, it has 2 sites for asparagine 
glycosylation, four potential protein kinase C phosphorylation sites, and five creatine 
kinase 2 phosphorylation sites.  Protein kinase C includes a variety of isoenzymes which 
serve multiple functions.  In relation to this study, novel PKC’s (particularly PKCθ) have 
been shown to be stimulated by free fatty acid accumulation, inhibit insulin receptor 
substrate 1 (IRS1) function and are elevated in insulin-resistant individuals.  Conversely, 
atypical PKC’s (e.g. PKCλ) have been shown to increase GLUT4 translocation.  The 
presence of potential protein kinase C phosphorylation sites on visfatin suggests that it 
may be influenced by these signaling proteins which are part of the insulin signaling 
pathway.  The presence of creatine kinase phosphorylation sites may further indicate a 
possible metabolic role of visfatin, as creatine kinase is an energy-sensing enzyme 
which facilitates the production of ATP and creatine from creatine phosphate and ADP.   
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Plasma visfatin has been shown to be upregulated in states of inflammation (Tilg 
and Moschen 2008; Li, Yang et al. 2009; Chang, Chang et al. 2010; Friebe, Neef et al. 
2011), hyperglycemia, and obesity (Fukuhara, Matsuda et al. 2005; Frydelund-Larsen, 
Akerstrom et al. 2007; Brema, Hatunic et al. 2008; Haus, Solomon et al. 2009).   The 
preprotein lacks a typical signal sequence for secretion; however, this does not preclude 
its secretion from tissue.  Visfatin has been found in the conditioned medium of multiple 
cell types as well as the blood, suggesting that it is secreted.  Research is lacking, but it 
has been suggested that visfatin is secreted through a non-classical secretory pathway 
(Revollo, Korner et al. 2007).   
 Visfatin also acts as a rate-limiting enzyme in the NAD biosynthetic pathway 
(Revollo, Grimm et al. 2004).  Visfatin has been shown to catalyze the conversion of 
nicotinamide and phosphoribosylpyrophosphate (PRPP) into nicotinamide 
mononucleotide (NMN).  Following this step, NMN is then converted to NAD+.  Because 
of this activity, Revollo and colleagues (2004) coined visfatin as nicotinamide 
phosphorybiosyltransferase (NAMPT).  This pathway is shown in Figure 1. 
 In 2005, Fukuhara and colleagues found that PBEF is preferentially expressed in 
the visceral fat of humans when compared to subcutaneous fat of the same subjects and 
renamed it visfatin.  In addition, they found visfatin to act as an insulin-mimetic by 
binding to the insulin receptor at a site different from insulin. Lastly, independent of 
insulin binding, visfatin caused autophosphorylation of the beta subunits of the receptor.  
The specifics of visfatin’s proposed insulin-sensitizing abilities will be discussed in the 
next section. 
In summary, this protein has many possible actions and as a result of its 
association with numerous physiological pathways, it has been given three different 
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names.  However for consistency, in the current review of the relevant literature, the 
term visfatin will consistently be used regardless of which name was used in the 
publication cited.   
 
Figure 1. NAD Biosynthesis Pathway. NAMPT represents the rate-limiting enzyme of the 
pathway.  NAMPT – Nicotinamide phosphoribosyltransferase, NMN – Nicotinamide 
mononucleotide, NmnaT – Nicotinamide mononucleotide adenylyltransferase, SIR2 – Sirtuin 
Protein
 
 
 
Visfatin as an Insulin Sensitizer 
 
The first study which suggested that visfatin had a possible insulin-sensitizing 
role was completed by Fukuhara et al (2005).  They found that an injection of 
recombinant visfatin into C57BL/6J obese mice lead to an insulin-independent increase 
in glucose uptake with a concomitant decrease in blood glucose.  Blood glucose was 
further decreased as the visfatin dose was increased.  Furthermore, this effect was 
unchanged in type II diabetic mice and when insulin production was inhibited by 
streptozotocin in healthy mice.  Through western blotting, they found that this increase in 
glucose uptake was related to an increase in phosphoinositide-3-kinase (PI3K) activity, 
and insulin receptor substrate (IRS) activity.  This was the first study to examine the 
metabolic effects of visfatin.  Fukuhara and colleagues (2005) concluded that visfatin 
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has the potential to act as an insulin-mimetic and play a significant role in insulin 
sensitivity.  In 2007, this study was retracted due to disputes regarding the human 
adipose tissue used to determine a correlation between body fat and visfatin (Fukuhara, 
Matsuda et al. 2007).  Their findings concerning visfatin’s correlation to visceral fat were 
later refuted, but the glucose-mediating properties of visfatin were supported in other 
studies (Xie, Tang et al. 2007; Song, Lee et al. 2008). 
The first study to support the findings from Fukuhara and confirm that visfatin had 
an insulin sensitizing effect was completed by Xie and colleagues (2007). In this study, 
cultured human osteocytes were used to further examine the effect of visfatin on insulin 
signaling proteins.  Glucose uptake was increased in a dose-dependent fashion when 
visfatin was administered to cultured cells without the presence of insulin.  An identical 
response was seen when insulin was administered to cultured cells without visfatin 
present.  This visfatin-induced increase in glucose uptake was shown to be due to an 
increase in the tyrosine phosphorylation of IRS-1, as well as the insulin receptor.  These 
data support the claims made by Fukuhara and colleagues that visfatin acts as a non-
competitive insulin-mimetic hormone and thus, has the potential to partially improve 
insulin sensitivity. 
Similarly, Song and colleagues (2008) used cultured mesangial cells (renal 
smooth muscle cells) from the renal cortex of healthy Sprague-Dawley rats to examine 
the relationship between glucose and visfatin.  Similar to the aforementioned studies, 
they found that administration of visfatin increased glucose uptake in cultured cells.  This 
study was novel in that they also investigated the effect of high glucose levels on visfatin 
synthesis.  They found that a higher dose of glucose administered to cultured cells lead 
to an increase in visfatin mRNA and protein concentration.  Furthermore, this was the 
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first study to look at the effect of altered levels of glucose on visfatin and the first study to 
show that mesangial cells can produce visfatin. 
Revollo et al (2007) further examined visfatin’s role in insulin sensitivity by 
comparing normal mice with visfatin-deficient mice using visfatin-knockout models.  In 
this study, visfatin was not found to act as an insulin-mimetic.  This was shown both in 
vivo and in vitro.  This was determined by examining phosphorylation of the insulin 
receptor and IRS-1.  While these results refute data from Xie et al (2007) PI3K 
phosphorylation was not determined.  PI3K is another proposed site for visfatin action, 
so data regarding PI3K phosphorylation would have provided further evidence for the 
claim in this study that visfatin has no insulin-mimetic capabilities.   Interestingly, this 
study showed that visfatin-deficient mice had impaired glucose tolerance and reduced 
glucose-induced insulin secretion.  Furthermore, visfatin was shown to enhance the 
secretion of insulin from pancreatic β-cells.  This is a significant finding as it is the first 
evidence that visfatin has direct action on insulin secretion at the level of the pancreas, 
but the specific mechanism of action is not fully understood.  While the authors 
concluded that visfatin does not act as an insulin-mimetic, they did concede that visfatin 
plays a major role in metabolism, but suggest this role is based on visfatin’s action as an 
enzyme in the NAD salvage pathway.  The metabolic significance of this enzymatic role 
is explained in a later section and is shown in figure 1. 
The correlation of visfatin to glucose homeostasis has been summarized in a 
recent meta-analysis by Chang and colleagues (Chang, Chang et al. 2011).  In this 
study, 46 articles which investigated the level of visfatin in cardiovascular disease, T2D, 
metabolic syndrome, and insulin resistance were analyzed.  They found visfatin to be 
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significantly elevated and correlated to other inflammatory markers in each study 
regardless of the chronic disease investigated.   
In summary, multiple studies have shown visfatin plays a role in glucose uptake.  
Visfatin has also been shown to be elevated in multiple conditions associated with 
impaired glucose homeostasis.  The action that visfatin has on the insulin signaling 
pathway may be at the insulin receptor as well as IRS1 and PI3K in a manner 
independent of insulin, but these claims are highly controversial.  A summary of the 
signaling pathway alterations relative to these findings are shown in figure 2.   
Visfatin and Inflammation 
Chang and colleagues investigated the relationship between visfatin mRNA and TNF-α 
(Chang, Chang et al. 2010).  They found that visfatin mRNA was positively correlated to 
both TNF-α and the macrophage-specific marker CD68+, while the levels of visfatin 
mRNA were not significantly different in visceral compared to subcutaneous adipose 
tissue.  While the authors concluded that visfatin must be strongly involved in the 
inflammatory process, there are several limitations to this study. A major limitation of this 
study is that visfatin mRNA was measured and protein concentration was not.  This 
limits the study in that mRNA levels are not always indicative of protein levels or of 
protein action as mRNA must be translated in order to form the active protein.  
Additionally, subjects involved in this study were obese, non-diabetic subjects.  Obesity 
is associated with a state of chronic low grade inflammation and high levels of TNF-α 
and CD68+ would be expected.  Furthermore, since visfatin has been shown to be 
correlated to the amount of fat present, a high level of visfatin would be expected in an 
obese population.  The fact that the two are correlated does not necessarily indicate any 
kind of causal relationship, and the correlation noted in the study may be coincidental.   
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Figure 2. Proposed Action of Visfatin on IRS1. Stars represent sites where visfatin has been 
shown to enhance phosphorylation.  TNF-α and JNK are also shown as they have a direct 
influence on IRS1 activity. 
 
 
Finally, this study also demonstrated that visfatin was correlated to blood 
glucose.  While the authors concluded their findings to show that visfatin is more of a 
cytokine than a metabolic hormone, this conclusion seems premature considering 
visfatin protein levels were not measured and the characteristics of the subjects used 
could significantly alter the relationships investigated. 
Li and colleagues (2008) examined plasma visfatin as well as visfatin mRNA by 
examining the effect of tumor necrosis factor alpha (TNF-α) on visfatin, insulin, and 
blood glucose in obese mice.  They found that a high dose of TNF-α administered via 
jugular catheter resulted in a decrease in plasma visfatin and visfatin mRNA in adipose 
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tissue of healthy mice.  Additionally, they found that TNF-α administration lead to dose-
dependent increases in blood glucose and insulin levels.  This study demonstrates a 
negative correlation between the pro-inflammatory cytokine TNF-α and visfatin.  While 
TNF-α has been previously shown to be a significant pro-inflammatory cytokine, the 
reason for this correlation may not necessarily be related to inflammation.  In addition to 
its pro-inflammatory function, TNF-α also influences metabolism by regulating 
lipogenesis, lipolysis, and decreasing insulin action (Uysal, Wiesbrock et al. 1997; Uysal, 
Wiesbrock et al. 1998).  While visfatin has been shown to be correlated to inflammation, 
the reason for the relationship found in this study may be due to metabolic properties of 
both cytokines.  If visfatin does increase glucose uptake, it is possible that the decrease 
in glucose uptake elicited by TNF-α may be partially due to inhibition of visfatin release.  
As this is the only study which has investigated TNF-α administration on visfatin, their 
relationship needs further investigation. 
 Romacho and colleagues further investigated the pro-inflammatory function of 
visfatin by examining its effect on signaling proteins associated with vascular 
inflammation (Romacho, Azcutia et al. 2009).  In this study, cultured human aortic 
smooth muscle cells were treated with recombinant visfatin.  Visfatin elicited an increase 
in extracellular-signal regulated kinase (ERK) 1 and 2 and nuclear factor kB-inducible 
and nitric oxide synthase (iNOS).  Nitric oxide synthase activation is associated with 
vascular damage and inflammation.  The increase in iNOS found was dose-dependent 
and lead the authors to conclude that visfatin was a direct contributor to inflammation.  
This is the only current research which shows visfatin to have a direct effect on the 
inflammatory signaling process.  If these results are substantiated, it makes visfatin a 
unique hormone in that there is evidence showing it to be pro-inflammatory as well as 
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insulin-sensitizing. This is unique and somewhat paradoxal, since the majority of pro-
inflammatory cytokines (TNF-α, IL-6, etc) have been associated with insulin resistance. 
Moschen and colleagues (2009) examined the relationship between visfatin and 
inflammation by investigating its role in inflammatory bowel disease and bone disease.  
They found that visfatin levels were positively correlated with disease activity and 
negatively correlated with bone mineral density.  Additionally, visfatin inhibited osteoclast 
differentiation in vitro.  While visfatin was concluded to be an inflammatory mediator, this 
study correlated visfatin to states of inflammation, but showed no causation.  
Additionally, glucose was not measured, so no conclusions can be drawn regarding the 
action of visfatin on glucose mediation. 
Friebe and colleagues (Friebe, Neef et al. 2011), correlated plasma visfatin levels 
with a variety of variables.  They found plasma visfatin levels to be positively correlated 
to body mass index (BMI) and blood glucose concentration, as well as strongly 
correlated to white blood cell counts in adolescent children.  These findings are not 
novel, but they do further support the concept that visfatin is associated with obesity and 
glucose metabolism.  Interestingly, they also found that visfatin was decreased 60 
minutes after oral glucose ingestion. This finding is in direct contrast to previous data 
(Hofso, Ueland et al. 2009), which showed that visfatin transiently increased 60 minutes 
after oral glucose ingestion. The disparity between these 2 studies may be related to the 
study population investigated or the time of sampling. Hofso et al. (2009) looked at 
morbidly obese adults, while Friebe et al. (2011) looked at lean and obese children.   
Another novel result of the Friebe et al. study was a strong correlation between 
neutrophils and visfatin.  This is significant since it is the first study to show a relationship 
between neutrophils and visfatin in non-diseased individuals.  Furthermore, the highest 
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level of visfatin mRNA was found in neutrophils when compared with mRNA levels in 
adipose and liver tissue.  The finding of leukocytes as a major source of visfatin is 
significant as well, considering visfatin was originally believed to be preferentially 
expressed by adipose tissue.  It is important to note, however, that once again, this was 
found to be true in obese individuals.  This provides evidence that visfatin may contribute 
to the low-grade chronic inflammation associated with obesity as well as contribute to 
alterations in glucose metabolism. 
In summary, visfatin appears to be linked to inflammation.  This is true in 
instances of obesity as well as inflammation in otherwise healthy individuals.  While 
several studies have shown correlations between visfatin and certain inflammatory 
markers, research investigating the pathways connecting visfatin to other inflammatory 
markers is lacking.  Additionally, visfatin may be elevated in cases of both altered 
elevated blood glucose and inflammation.  Obesity was first shown to be connected to 
inflammation in 1993 when it was demonstrated that TNF-α is highly expressed in 
adipose tissue (Hotamisligil, Shargill et al. 1993) furthermore, inflammatory cytokines 
have been shown to be highly expressed in both obese and non-obese hyperglycemic 
individuals (Esposito, Nappo et al. 2002). In a previous study, ingestion of 75g of 
glucose was found to stimulate reactive oxygen species production by leukocytes in non-
obese subjects (Mohanty, Hamouda et al. 2000).  It is difficult to separate these findings 
on inflammation and blood glucose, as subjects who are hyperglycemic are often obese 
and therefore in a state of low-grade inflammation.   
Visfatin and Acute Exercise 
 To date, limited studies have been conducted investigating the response of 
visfatin to acute exercise.  In 2006, Frydelund-Larsen and colleagues investigated the 
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response of visfatin mRNA in adipose tissue and skeletal muscle after three hours of 
cycle ergometer exercise done at 60% VO2 max in healthy young men.  Visfatin mRNA 
in subcutaneous abdominal adipose tissue was elevated three fold immediately after 
exercise, 3, 4.5, and 6 hours post exercise.  Visfatin mRNA in skeletal muscle was not 
affected by exercise, nor was plasma visfatin.  Visfatin mRNA in subcutaneous adipose 
tissue was elevated post exercise and accompanied by a significant increase in IL-6 
mRNA in subcutaneous adipose tissue as well as a significant decrease in blood 
glucose.  Long-term endurance exercise has been shown to increase glucose uptake 
independent of insulin.  The increase in visfatin mRNA in adipose tissue and not in 
skeletal muscle may be due to an alteration in the insulin/glucagon ratio seen with such 
long-term exercise.  The reason for the lack of change in plasma visfatin may be due to 
the fact that the subjects were healthy young men with low visfatin concentrations.  
Additionally, how visfatin is secreted and where it is secreted from is still not fully known.  
Visfatin mRNA’s role in glucose metabolism post-exercise is difficult to fully understand, 
but according to these data, there is a correlation.   
The first study to measure peripheral (plasma) visfatin concentration after acute 
exercise was an endurance (aerobic) exercise study using highly-trained rowers as 
subjects (Jurimae, Ramson et al. 2009).  In this study, nine young rowers took part in a 
two hour rowing session performed at 80% of maximum heart rate. Visfatin decreased 
by 0.06 ng/ml 30 minutes post-exercise.  Insulin decreased from 12.4 ul/ml to 4.1 ul/ml 
30 minutes after exercise.  These values were also corrected for shifts in plasma 
volume.  The decrease in visfatin seen with this study may be due to the insulin-
independent increase in glucose uptake that is accompanied with acute exercise 
(Hawley and Lessard 2008).  An acute bout of endurance exercise decreases insulin 
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output partially due to an increase in epinephrine and norepinephrine which both inhibit 
insulin release.  Additionally, blood glucose decreases with acute exercise due to insulin-
independent increased glucose uptake.  If visfatin responds to blood glucose, then 
visfatin would decrease similarly to insulin as blood glucose is lowered after acute 
exercise.  The results from this study, again, provide evidence for visfatin as an insulin-
mimetic as it shows visfatin to mirror the exercise-induced changes in blood glucose in a 
pattern similar to insulin.  
 The other study which examined acute exercise and plasma visfatin response 
was significantly different in that high intensity exercise was used as a treatment 
(Ghanbari-Niaki, Saghebjoo et al. 2010).  In this study, physically fit men performed 7 
sets of six 35 meter sprints after a 10-minute warm up.  Immediately after exercise, 
plasma visfatin, insulin, and blood glucose were all increased almost two fold.  Forty five  
minutes post-exercise, all variables had returned to pre-exercise levels.  Both blood 
glucose and insulin have previously been shown to be increased after short-term high 
intensity exercise (MacDougall, Ward et al. 1977), this is however the only study to show 
visfatin to increase after acute exercise. As the subjects used in this study were healthy 
(non-obese, non-diabetic), the increase in visfatin was not likely due to impaired glucose 
uptake.  Instead, visfatin may mediate the insulin response to exercise or possibly 
augment insulin’s effect on glucose uptake at the muscle.   
Studies have shown glucose and visfatin to be linked, and research suggests 
that visfatin has an insulin-mimetic role (Fukuhara, Matsuda et al. 2005; Xie, Tang et al. 
2007).  It is still unclear what exactly drives visfatin alterations in the blood. Some 
research suggests that glucose alterations drive visfatin concentrations (Ghanbari-Niaki, 
Saghebjoo et al. 2010), but initial studies suggest the opposite may be true (visfatin 
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drives glucose) (Fukuhara, Matsuda et al. 2005). Current literature does not allow a 
definitive conclusion about this and studies investigating the glucose and visfatin 
response in healthy individuals is lacking. Thus, the currently proposed research is 
paramount for understanding this simple issue; does glucose drive visfatin 
concentrations, does visfatin drive glucose concentrations or are visfatin and glucose 
changing in parallel due to another driving force.  A summary of these studies are shown 
in table 1.  
 
Table 1. Summary of Acute Exercise Studies 
Study Subjects 
Length/Intensity 
of Treatment 
Pre-Test 
Visfatin 
(ng/ml) 
Post-test 
Visfatin 
(ng/ml) 
Insulin 
Response 
(pre - post) 
Blood 
Glucose 
Response 
(pre - post) 
Frydelund et 
al. (2006) 
Healthy 
Young Men 
3 hr cycling 
@60% of VO2 
max 
20.6* 24.9 
49.3 - 30.6* 
(pmol/l) 
5.1 - 4.6 
(pmol/l)  
Jurimae et 
al. (2008) 
Elite Rowers 
2 hr rowing 
@80% Heart 
Rate Reserve 
6* 5.4* 
12.7 - 3.9* 
(IU/l) 
4.1-4.1 
(mmol/l) 
Niaki et al. 
(2010) 
Healthy 
Kickboxers 
7 sets of 6 x 35 
m sprints 
(about 20 min) 
12* 26* 7 – 13* (IU/l) 
6 – 8* 
(mmol/l) 
*α < 0.05 
 
Visfatin and Chronic Exercise Training 
 While research regarding exercise training and visfatin is somewhat varied, the 
consensus is that exercise training elicits a decrease in plasma visfatin.  The first study 
which examined plasma visfatin with exercise training was done in 2006 with type 1 
diabetic individuals (Haider, Pleiner et al. 2006).  Aerobic exercise sessions were 
performed on a cycle ergometer working up to 70% maximal oxygen consumption 
(VO2max) twice per week for eight months.  Visfatin was found to be decreased 2 
months into training, further decreased 4 months into training, and even further 
21 
 
decreased after training when compared to baseline.  Neither BMI nor fasting blood 
glucose was changed with exercise training.  Baseline visfatin in type I diabetic subjects 
was significantly higher than healthy controls.  The elevated visfatin level seen in type I 
diabetics may be an attempt to enhance glucose uptake through visfatin’s insulin-like 
effect on GLUT4 translocation or its action to increase insulin secretion from the 
pancreas.  Exercise training augments glucose uptake independent of insulin (Hawley 
and Lessard 2008) by increasing GLUT4 translocation and by increasing adenosine 
monophosphate dependent kinase (AMPK).  Because glucose uptake is enhanced by 
exercise training, plasma insulin levels are decreased in a healthy population.  If visfatin 
is an insulin-mimetic hormone, then a decrease in visfatin with exercise training would 
be expected (similar to insulin).  The training-induced decrease in insulin is often 
accompanied by a decrease in blood glucose in those with elevated blood glucose.  
While other training studies have shown decreases in plasma visfatin to be related to 
decreases in blood glucose, blood glucose did not change in this study. It is possible that 
the decrease in visfatin was not metabolic, but more due to its enzymatic NAMPT activity 
or the inflammatory action of visfatin.  
 A separate study by Choi and colleagues found a similar visfatin response in 
non-obese subjects (Choi, Kim et al. 2007).  In this study, both obese and non-obese 
subjects trained aerobically five times per week for 12 weeks.  Exercise was performed 
using a cycle ergometer at an intensity of 60-70% of maximum heart rate.  Training 
elicited a significant decrease in resting blood glucose, weight, BMI, body fat 
percentage, and plasma visfatin in obese individuals.  In non-obese individuals, training 
did not lead to a decrease in visfatin but did lead to a decrease in resting blood glucose 
and BMI.  The decrease in visfatin in the obese individuals in response to exercise 
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training may be due to several reasons. First, as previously stated, visfatin has been 
correlated to fat mass and a reduction in fat (37.6% to 32.2%) was seen with this study.  
Additionally, after training, fasting blood glucose was decreased, which could have led to 
a decrease in visfatin, as visfatin has also been correlated to blood glucose.  Similar to 
the Haider (2006) study, this decrease in blood glucose and visfatin may also be due to 
an enhancement in glucose metabolism seen with exercise training.  As previously 
stated, exercise training enhances glucose uptake independent of insulin.  The fact that 
visfatin was not altered in non-obese subjects is somewhat difficult to explain.  As fasting 
blood glucose and BMI both were decreased, one would expect plasma visfatin to also 
decrease.  The reason that visfatin did not decrease may be due to the fact that these 
subjects were not hyperglycemic or obese and did not have elevated visfatin levels at 
baseline. It is possible that one reason for the associative decreases in plasma visfatin, 
blood glucose, and BMI seen in obese individuals with exercise training is that visfatin 
levels are returning to those of healthier individuals.  Further research regarding plasma 
visfatin and healthy individuals is needed to further explain these results. 
In T2D patients, 12 weeks of aerobic training led to a decrease in plasma visfatin 
(Brema, Hatunic et al. 2008).  This study was novel in that it was the first study to show a 
change in plasma visfatin with exercise training in T2D patients.  Similar to a type I 
diabetic population, plasma visfatin is elevated in the presence of T2D when measured 
at rest.  Plasma visfatin appears to be elevated in all instances of impaired insulin 
function (T2D, T1D, and insulin resistance).  This suggests that visfatin may play a 
significant role in insulin action.  In type I diabetes, insulin is not produced by pancreatic 
beta cells.  Visfatin may be elevated in order to increase glucose uptake in the absence 
of insulin.  In T2D, insulin action is impaired.  In order to maintain glucose homeostasis 
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and reduce blood glucose, more insulin is produced.  If visfatin is an insulin-mimetic, 
then elevations in plasma visfatin would be correlated to high levels of insulin.  
Furthermore, the fact that plasma visfatin is elevated in a T2D population is probably due 
to both an impairment of insulin signaling and an increase in body fat associated with 
T2D.  This study, however, showed a decrease in visfatin with exercise training without 
showing any decreases in body fat or BMI.  This evidence suggests that the elevated 
visfatin seen in T2D patients is attenuated by exercise training, independent of changes 
in body fat or weight.  This however needs to be confirmed with other studies.  
 Haus and colleagues further investigated the impact of exercise training on 
plasma visfatin by studying non-diabetic obese men (Haus, Solomon et al. 2009).  
Aerobic exercise was done at 60% of HR max at the start of the study and increased up 
to 85% of HR max by the end of the 12-week training program.  Training elicited a 
significant decrease in overall body fat, body weight, BMI, resting blood glucose, and a 
decrease in plasma visfatin.  Additionally, a strong correlation (r = 0.80) was found 
between percentage change in visceral adipose tissue and percentage change in 
plasma visfatin.  Furthermore, correlations were found between percentage change in 
plasma visfatin and percentage change in resting insulin as well as percentage change 
in plasma visfatin and percentage change in resting blood glucose (r = 0.52 and r = 0.53 
respectively).  While the decrease in visfatin with training was not a novel finding, this 
study showed a correlation between visfatin and resting blood glucose, and 
consequently a link between visfatin and improved glucose tolerance or regulation in an 
obese population.   
A recent study examined plasma visfatin and glucose metabolism in adolescent 
obese females after a 12 week training program (Lee, Shin et al. 2010).  Training in this 
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study consisted of 40-50 minute aerobic sessions with a caloric expenditure of 400-500 
kcal.  Exercise was performed 4 times per week for 12 weeks.  Once again a decrease 
in plasma visfatin was shown.  The decrease in plasma visfatin reported  in this study 
was greater than previous studies (almost a 35% decrease).  Furthermore, insulin and 
insulin resistance (via HOMA-IR) were reduced after training.  This alteration in plasma 
visfatin and glucose regulation was accompanied by a decrease in overall body fat and 
BMI which is to be expected with obese subjects.   
 The most recent study involving plasma visfatin and exercise training was done 
using older (mean age of 53yrs ) T2D patients as subjects (Jorge, de Oliveira et al. 
2011).  This study used the novel approach of resistance training as well as aerobic 
training.  Again, a 12-week protocol was used.  Aerobic training was performed 3 days 
per week for 60 minutes on a cycle ergometer at an intensity equal to the lactate 
threshold (moderate intensity).  Resistance training consisted of a 7-exercise circuits 
involving major muscle groups done 3 times per week.  In this study, visfatin was found 
to be increased after training.  The increase was not different between resistance 
exercise, aerobic training, or a combined protocol in this study.  Additionally no changes 
were observed in BMI, insulin resistance (assessed via HOMA-IR), or TNF-α, but a 
decrease was seen in C-reactive protein (CRP).  These data are in contrast to other 
research which has shown visfatin to correlate to inflammatory markers as well as 
glucose metabolism.  The increase in visfatin was not only in opposition to the other 
inflammatory markers measured, but also did not correspond to changes in fat or other 
markers of insulin resistance.  One possible reason for this increase could be due to the 
increase in ATP demand in this study.  This mechanism will be discussed further in a 
later section. 
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 In summary, aerobic exercise training tends to lower plasma visfatin levels.  This 
has been shown to be true in multiple studies.  Often, this decrease is accompanied by a 
decrease in body fat or a decrease in BMI (Choi, Kim et al. 2007; Haus, Solomon et al. 
2009; Lee, Shin et al. 2010) and is often accompanied by decreases in resting  blood 
glucose or insulin (Brema, Hatunic et al. 2008; Haus, Solomon et al. 2009; Lee, Shin et 
al. 2010).  The majority of training studies have also examined the visfatin response 
during states of altered glucose metabolism such as diabetes (Type I and II) or obesity 
(Haider, Pleiner et al. 2006; Brema, Hatunic et al. 2008; Haus, Solomon et al. 2009; Lee, 
Shin et al. 2010; Jorge, de Oliveira et al. 2011).  The decrease in plasma visfatin seen 
with exercise training may be due to an enhancement of glucose uptake as blood 
glucose has been shown to be decreased in the majority of training studies.  
Additionally, the decrease in plasma visfatin may be due to a decrease in visfatin 
secretion after blood glucose is decreased.  The link between blood glucose and plasma 
visfatin is still not fully understood, but based on the exercise training literature, it does 
appear that blood glucose and plasma visfatin are related.  However, two studies have 
shown visfatin to be increased independent of blood glucose concentration or insulin 
(Haider, Pleiner et al. 2006; Jorge, de Oliveira et al. 2011).  The reason for a change in 
plasma visfatin without a change in blood glucose or insulin is difficult to discern. This 
may be related to visfatin release or inflammation independent of glucose regulation.   It 
is possible that the reason plasma visfatin increased may be due to its enzymatic action 
or possible pro-inflammatory effects.  A summary of these studies is presented in table 
2. 
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Table 2. Summary of Chronic Exercise Studies 
Study Subjects 
Length of 
Study 
Pre-Training 
Resting 
Visfatin 
(ng/ml) 
Post-
Training 
Resting 
Visfatin 
(ng/ml) 
Insulin (iu/l 
pre - post) 
Blood 
Glucose 
(mg/dl pre - 
post) 
Haider et al. 
(2006) 
Type I 
Diabetic 
4 Months 64.1 27.8* N/A 151 – 125 
Choi et al. 
(2007) 
Obese 12 weeks 16.4                 7.7* 13.8-10.9*  82-77*      
 Non-Obese 12 Weeks 7.7 7.7 13-10 90- 81* 
Brema et al. 
(2008) 
T2DM 12 weeks 64.7 29.5* N/A N/A 
 Obese 12 Weeks 55.8 11.6* N/A N/A 
Haus et al. 
(2009) 
Obese 12 weeks 17 13* 
45.8 - 35.3* 
(mmol) 
450 – 392* 
(mmol) 
Jorge de 
Oliveira et 
al. (2011) 
Obese 12 weeks 112 131* 156 – 148 N/A 
* α = 0.05 
In summary, the response of visfatin to exercise appears to be dependent on the 
duration, intensity, and the characteristics of subjects involved.  Visfatin has been shown 
to be decreased after exercise training, and this decrease is often associated with a 
decrease in body fat and resting blood glucose.  In contrast, visfatin has been shown to 
be both increased and decreased after acute exercise.  The differences in these results 
are likely due to exercise intensity and subject characteristics.  Generally speaking, 
visfatin will decreases in subjects who have higher resting visfatin levels and higher 
blood glucose levels after training.  This is more evident in studies which have used 
obese individuals or T2D patients as subjects.  Furthermore, although studies are 
limited, higher intensity exercise has been shown to initiate an increase in plasma 
visfatin in a matter similar to that of insulin. 
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Visfatin and Energy Demand 
 In addition to the role that visfatin may play in glucose homeostasis, visfatin may 
be involved during exercise through its enzymatic action as NAMPT.  This was shown in 
rats by Koltai and colleagues in 2010 (Koltai, Szabo et al. 2010).  In this study, rats were 
trained for 6 weeks, at 60% VO2 max.  After exercise, relative enzymatic activity of 
NAMPT was increased as was sirtuin1 (SIRT1) in the gastrocnemius.  SIRT1 is an 
NAD+-dependent protein deacetylase which helps to regulate muscle differentiation and 
repair, and also plays a role in metabolism (Bhakat, Mokkapati et al. 2006).  Exercise 
training led to an increase in the availability of NAMPT protein and a concomitant 
increase in NAD+.  The reason for increases in both visfatin and SIRT1 may be due to 
SIRT1’s muscle cell differentiation ability but are more likely metabolically related.  With 
exercise training, an increase in NAD+ availability is expected as is an increase in 
glycolytic flux.  As blood glucose was not measured, it is impossible to establish a 
connection between glucose, visfatin, SIRT1, and exercise in this study.  That being 
said, it does appear that visfatin’s connection to blood glucose may also be affected by 
its significant role in NAD+ availability.  
 A similar study was conducted by Hokari and colleagues in male rats which were 
trained 7 days per week (Hokari, Kawasaki et al. 2010).  In this study, a significant 
increase was seen in SIRT3, and in NAD+, but not in NAMPT in the soleus, plantaris, 
and triceps muscles of exercised rats.  These data suggest that NAMPT may be more 
active in SIRT1 activation or that a greater increase in NAD+ is required to see significant 
changes in NAMPT.  NAD+ increased by almost 100% in the previous study (Koltai, 
Szabo et al. 2010) compared to 49% in this study.  Furthermore, sirtuins have been 
shown to improve insulin sensitivity (Sun, Zhang et al. 2007), again providing a link 
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between visfatin and enhanced insulin signaling.  The exact relationship between 
visfatin, sirtuin proteins, and insulin sensitivity is not fully known and further investigation 
is required. 
 The relationship between visfatin and energy demand has also been investigated 
in humans (Costford, Bajpeyi et al. 2010).  In this study, visfatin was significantly 
correlated to mitochondrial mass, AMPK activity, and glucose disposal rate in the 
gastrocnemius. This was determined by a cross-sectional analysis of athletes and obese 
individuals as well as through a moderate training intervention.  After the cross-sectional 
analysis, obese individuals underwent a 3-week aerobic training program (intensity and 
duration not stated).  After 3 weeks of training, NAMPT protein concentration was 
increased 127%.  Furthermore, when AMPK was activiated via AICAR in vitro, visfatin 
mRNA was increased 3.4 fold.  These data suggest that visfatin plays a vital role in 
energy demand within muscle.  Exactly what this role is remains unclear.    
Visfatin and Feeding 
 To our knowledge, no research has been done to investigate the acute response 
of visfatin to feeding of any kind in healthy individuals.  Considering visfatin has been 
shown to be higher in those with higher fat diets and higher blood glucose (de Luis, 
Gonzalez Sagrado et al. 2008; de Luis, Aller et al. 2010), one could speculate that 
visfatin is elevated by a higher caloric intake.  Furthermore, this study did not control for 
body fat.  Considering visfatin is correlated to total body fat, the elevated visfatin seen 
with chronic overeating of fat and glucose may be due to excess body fat.  The acute 
response of visfatin to general caloric intake or specific macronutrients is unknown. 
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High-Intensity Exercise and Metabolism 
 In 1977, MacDougall and colleagues demonstrated that muscle glycogen was 
drastically decreased immediately after high intensity intermittent exercise (MacDougall, 
Ward et al. 1977).  Twenty-four hours after exercise, muscle glycogen levels were 
increased back to pre-exercise levels, and were increased beyond pre-exercise levels in 
carbohydrate-loaded subjects.  These changes in muscle glycogen were accompanied 
by elevations in blood glucose.  Decreases in muscle glycogen were followed by an 
increase in blood glucose delivery to the muscles and vice versa.  The reason for this is 
that high intensity exercise requires muscle glycogen as a fuel source.  As exercise 
intensity (or duration during long-term exercise) increases and muscle glycogen is 
further decreased, glucose output from the liver is increased to replenish muscle 
glycogen stores, and thus, blood glucose delivery to the muscle is increased. 
 Furthermore, insulin levels and glucose concentrations have been shown to be 
decreased during, and elevated shortly after a Wingate test (Moussa, Zouhal et al. 2003; 
Vincent, Berthon et al. 2004), exhaustive high-intensity exercise (MacDougall, Ward et 
al. 1977; Felsing, Brasel et al. 1992; Higaki, Kagawa et al. 1996; Zouhal, Vincent et al. 
2009), and circuit resistance training (Kraemer, Durand et al. 2004; Ghanbari-Niaki 
2006).  This increase in plasma glucose after high-intensity exercise is likely due to the 
inhibitory effect of cortisol and GH on glucose uptake which has been shown to lead to 
transient insulin resistance after high intensity exercise (Ghanbari-Niaki, Saghebjoo et al. 
2010).  Furthermore, elevated epinephrine decreases glucose uptake in non-working 
muscle, and increased norepinephrine stimulates liver glyogenolysis to enhance blood 
glucose.  This leads to an increase in glucose uptake, and muscle glycogen stores are 
replenished.  Whether or not this glucose uptake is partially mediated by visfatin is 
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unknown.  Finally, glucose ingestion prior to exercise has been shown to augment these 
alterations in blood glucose levels (Bacurau, Bassit et al. 2002). 
 Additionally, high intensity exercise has been shown to elicit significant increases 
in glucagon.  This has been shown with an exercise volume as low as 3 x 300m sprints 
(Naveri, Kuoppasalmi et al. 1985).  In this study, a twofold increase seen in blood 
glucagon immediately after exercise was accompanied by a twofold increase in blood 
glucose as well.  Furthermore, this increase was similar to an increase seen with 15 
minutes of continuous running.  The results seen in this study further show that short-
term high intensity exercise causes an immediate increase in blood glucose with a 
concomitant increase in glucagon. 
 In summary, exercise done at a high enough intensity and for long enough 
duration will lead to a decrease in muscle glycogen.  In order to replenish muscle 
glycogen stores, glucose uptake at the muscle is increased and blood glucose 
decreases.  In order to raise blood glucose, glucose output from the liver is increased, 
and blood glucose levels return to pre-exercise values. 
Visfatin and Insulin  
 Several studies have reported visfatin to act in the same matter as insulin.  This 
has been shown both after acute exercise (Ghanbari-Niaki, Saghebjoo et al. 2010; 
Jurimae, Gruodyte et al. 2011) and chronic exercise (Choi, Kim et al. 2007; Haus, 
Solomon et al. 2009).  Furthermore, resting visfatin levels have been shown to be 
elevated in individuals who have elevated insulin levels due to insulin impairment (T1D 
or T2D) (Haider, Pleiner et al. 2006; Choi, Kim et al. 2007; Haus, Solomon et al. 2009; 
Jorge, de Oliveira et al. 2011).  The possible link between insulin and visfatin was 
originally proposed to be due to visfatin’s potential action on the insulin receptor 
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(Fukuhara, Matsuda et al. 2005), but a more recent study has suggested that visfatin 
may act on the release of visfatin from the pancreas (Revollo, Korner et al. 2007).  In this 
study, nicotinamide mononucleotide (NMN) was intravenously administered to mice.  
This increase in NMN lead to an increase in visfatin and concomitant increase in insulin 
release from pancreatic beta cells.  The authors further suggested that the action visfatin 
may have on insulin release or action is due to its enzymatic action as NAMPT (figure 1).  
This is the only study to have examined the action of visfatin on the pancreas.  More 
research is needed to fully understand the enzymatic role of visfatin at the level of the 
pancreas. 
Exercise and Carbohydrate Supplementation 
 Multiple studies have investigated the use of carbohydrate supplementation prior 
to exercise to maintain blood glucose levels.  In 1986, Coyle and colleagues found 
ingestion of 2 grams of carbohydrates per kilogram of body weight taken in a solution of 
50% water improved performance and maintained blood glucose levels (Coyle, Coggan 
et al. 1986).  After 105 minutes of cycling at 70% of VO2max, carbohydrate-fed subjects 
did not have a significant decrease in blood glucose while the blood glucose of subjects 
not fed a carbohydrate solution decreased by 50%.  Additionally, fatigue was delayed by 
33% in carbohydrate-fed subjects.  Carbohydrate ingestion prior to prolonged exercise 
increases muscle glycogen synthesis by increasing available glucose as a substrate for 
glycogen and by increasing insulin to increase glucose uptake at the muscle.  
Furthermore, carbohydrate feeding during 4 hours of prolonged cycling increased blood 
glucose levels above pre-exercise levels (Hargreaves, Costill et al. 1984).   
Since the publication of these initial, ground breaking studies, multiple studies 
have shown glucose supplementation to sustain blood glucose and spare muscle 
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glycogen during prolonged exercise, short-term exercise, and resistance exercise 
(Jeukendrup, Brouns et al. 1997; Lancaster, Jentjens et al. 2003; Fernandez, Da Silva-
Grigoletto et al. 2010; Ghanbari-Niaki, Saghebjoo et al. 2010).  To summarize the effects 
of glycogen supplementation, The International Society of Sports Nutrition released a 
position statement.  In it, the following is stated; 
 
During exercise, CHO should be consumed at a rate of 30 - 60 grams of 
CHO/hour in a 6 - 8% CHO solution (8 - 16 fluid ounces) every 10 - 15 minutes. 
Adding PRO to create a CHO: PRO ratio of 3 - 4:1 may increase endurance 
performance and maximally promotes glycogen re-synthesis during acute and 
subsequent bouts of endurance exercise. 3.) Ingesting CHO alone or in 
combination with PRO during resistance exercise increases muscle glycogen, 
offsets muscle damage, and facilitates greater training adaptations after either 
acute or prolonged periods of supplementation with resistance training. 4.) Post-
exercise (within 30 minutes) consumption of CHO at high dosages (8 - 10 g 
CHO/kg/day) have been shown to stimulate muscle glycogen re-synthesis, while 
adding PRO (0.2 g - 0.5 g PRO/kg/day) to CHO at a ratio of 3 - 4:1 (CHO: PRO) 
may further enhance glycogen re-synthesis. (Kerksick, Harvey et al. 2008) 
 
  
 A more recent study done by Kraemer and colleagues (2011) showed that 
ingestion of a 350 kcal shake composed of 57% carbohydrates, 28% fat, and 15% 
protein maintained blood glucose levels for 90 minutes of prolonged exercise at 60% 
VO2 max in healthy individuals.  Subjects were supplemented 60 minutes prior to 
exercise and after an overnight fast.  While this study shows similar results to the 
aforementioned studies regarding glucose supplementation, it is relevant to this study as 
the methodology is similar.  Although in the current study, protein and fat are not being 
supplemented, the timing will be identical to the Kraemer study.  
 Carbohydrate supplementation of 50g of carbohydrate has also been shown to 
maintain blood glucose levels in anaerobic exercise more so than aerobic exercise 
(Fernandez, Da Silva-Grigoletto et al. 2010).  In this study, trained males performed two 
exercise sessions.  One session involved 30 minutes of cycling performed just below 
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anaerobic threshold while the other involved a series of squats at 80% of 1RM.  Glucose 
supplementation administered 15 minutes prior to exercise led to elevated blood glucose 
in both situations, but the elevation was augmented in the anaerobic group (7.5mmol/l in 
anaerobic and 6.0mmol/l in aerobic).  Again, both groups had higher blood glucose 
levels compared to no supplement. 
 In summary, ingestion of a carbohydrate mixture prior to exercise will attenuate 
the decrease in blood glucose usually seen with exercise.  While a variety of methods, 
solutions, and exercise intensities have been used, 50g of carbohydrates administered 
prior to exercise has been shown to augment elevations in blood glucose during and 
after anaerobic exercise (Fernandez, Da Silva-Grigoletto et al. 2010; Kraemer, Francois 
et al. 2011).  Furthermore, high-intensity intermittent exercise has been shown to 
increase plasma visfatin more so than moderate intensity exercise (Jurimae, Ramson et 
al. 2009; Ghanbari-Niaki, Saghebjoo et al. 2010).      
Summary 
 In summary, the response of visfatin to exercise is varied and dependent on 
many factors.  The majority of data regarding visfatin and exercise has been done using 
exercise training and obese individuals whose glucose homeostasis is altered.  
Additionally, only one study to date has examined visfatin after high intensity exercise.  
In order to further understand visfatin’s role in metabolism and exercise, it is necessary 
to investigate visfatin in a healthy population so that dysfunctional insulin signaling is not 
an issue.  Another possible link between visfatin and metabolic function is visfatin’s 
action as a rate-limiting enzyme in the NAD+ biosynthesis pathway.  Alterations in 
energy balance and ATP production (e.g. exercise) have been shown to lead to 
alterations in visfatin.  Since NAD+ availability plays a significant role in the rate of 
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glycolysis, increased visfatin may be linked to its ability to increase NAD+ availability as 
would be needed during exercise or when glucose uptake is increased. 
The current study is an attempt to examine the response of visfatin to alterations 
in blood glucose without the extraneous influence of altered glucose metabolism, 
obesity, or chronic inflammation.  While much research is still needed regarding all areas 
of visfatin function, the current study will attempt to delineate how visfatin changes in 
response to acute exercise coupled with elevations or decrements in blood glucose. 
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CHAPTER III 
METHODS 
Pilot Study 
 To determine the timing of glucose feeding and exercise intervals required to 
elicit the desired alterations in blood glucose and plasma visfatin, a pilot study was 
completed.  Two sprint-trained males (ages 24 & 28) were recruited and completed a 
series of exercise bouts.  Absolute mean power (AMP) was previously determined for 
both subjects using a Wingate test.  The intensity for the exercise bouts was 50% of the 
subject’s AMP.  In all sessions, after a six-minute warm up at an intensity of 50 watts, 4 
3-minute bouts of exercise were performed at 50% of AMP.  Each bout was separated 
by a six-minute active recovery period performed at an intensity of 50 watts.  Blood was 
drawn immediately prior to and immediately after each exercise bout.  In all testing 
sessions, blood glucose was determined using a commercially available glucometer 
(Bayer Contour).  Visfatin levels were determined in only one subject due to cost. 
During the glucose feeding trials, resting blood glucose was determined after an 
overnight fast.  Immediately following the resting fasted blood glucose determination, 
236 ml of Gatorade G01 prime was then ingested.  The macronutrient composition of 
this supplement included 50 g of carbohydrates, and 0g of fat or protein (200 Kcals).  
Additionally, there were 35 mg of potassium and 110 mg of sodium.  As there is no 
research regarding carbohydrate supplementation, exercise, and visfatin, timing and 
dosage of supplementation was based on a recent study done by Kraemer and 
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colleagues (Kraemer, Francois et al. 2011).  In summary, the following pilot testing 
sessions were completed; 
 
1. Subject 1, Pilot Trial 1; Glucose supplementation was given 60 minutes prior 
to exercise.  Only blood glucose was assessed due to cost.  Blood glucose 
peaked 30 minutes after supplementation but returned to baseline by the time 
exercise began.  These data are presented in Figure 3 with the black arrows 
representing the onset of each exercise bout. 
 
2. Subject 1, Pilot Trial 2; The timing for trial 2 was identical to trial 1.  Glucose 
supplementation, however, was not given and blood glucose was tested 
immediately prior to the onset of exercise.  Blood glucose remained relatively 
constant throughout exercise.  These data are presented in Figure 4 with the 
black arrows representing the onset of each exercise bout. 
 
0 
20 
40 
60 
80 
100 
120 
140 
160 
0 20 40 60 80 100 120 
B
lo
o
d
 G
lu
co
se
 (
m
g/
d
l)
 
Time 
Figure 3. Blood Glucose w/CHO Administration 60 min Prior to 
Exc 
Blood Glucose 
37 
 
 
3. Subject 2, Pilot Trial 3; After analysis of the first two trials, glucose 
supplementation was administered 30 minutes prior to exercise in order to 
begin exercise at the peak blood glucose value.  Both blood glucose and 
plasma visfatin were assessed in trial 3.  Plasma visfatin was assessed via 
commercially available ELISA kit (Raybiotech, Norcross, GA).  Both blood 
glucose and plasma visfatin appeared to respond similarly to the sprint 
exercise protocol. These data are presented in Figure 5 with the black arrows 
representing the onset of each bout. 
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Study Design 
Ten sprint-trained males, between the ages of 18 and 30, with less than 20% 
body fat (determined via 3-site skinfold assessment) were used as subjects.  A group of 
ten subjects was determined to be appropriate to yield a power of 0.80 with an alpha 
value of 0.05.  Sprint-trained males were chosen as subjects since this was a high-
intensity protocol, and it may have been too intense for someone who was not sprint-
trained.  Furthermore, as demonstrated by the pilot study, the desired alterations in 
blood glucose were reached when sprint-trained males acted as subjects.  As research 
is lacking regarding visfatin, females were not included in order to eliminate hormonal 
influences and increase homogeneity of the subject pool.  Sprint-trained was defined as 
participating in some form of high intensity interval exercise at least 2 times per week for 
at least the last 4 weeks using leg muscles that would be utilized for the Wingate and 
cycling.  The majority of subjects (N=6) cycled regularly.  Four subjects cycled at least 
100 miles per week.  Three subjects were crossfit competitors, 1 of which had competed 
on the national level.   
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Subjects returned to the lab on 2 separate occasions after a screening session.  
Each exercise session included a high-intensity interval exercise session, and either a 
carbohydrate supplement or a placebo (236 ml of sugar free kool-aid). Each supplement 
was given 30 minutes prior to exercise and was randomly determined based on a coin 
flip.   
Screening Session 
A screening session was completed prior to the exercise sessions.  During the 
screening session, informed consent was obtained, body composition and body fat 
distribution were determined through skinfold assessment, and abdominal circumference 
and BMI were assessed.  Resting heart rate, blood pressure, medical history, exercise 
history were assessed, and a 3-day dietary record was given to all subjects, which was 
completed for the 3 days prior to each exercise session.  Dietary records were analyzed 
for total caloric intake and macronutrient percentage using the software, my fitness pal.  
After subjects were considered eligible, total body was also determined through dual-
energy x-ray absorptiometry (DXA).  Truncal fat was also determined by DXA analysis.  
Truncal fat was determined as any fat located below the neck, and not on either limb.  
Truncal fat was assessed since it has been shown to be a direct indicator of the amount 
of visceral fat (Dwimartutie, Setiati et al. 2010).  Additionally, a Wingate test was 
completed to determine AMP.  Resistance during the Wingate test was 7.5% of body 
weight.  Absolute mean power was calculated as; 
 AMP (W) = load (Kg on flywheel) x average revolutions x 11.765   
 
In addition to AMP, absolute peak power (APP) and fatigue index (FI) were determined. 
 
 APP was calculated as; 
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Exc Session 1 
 APP (W) = load (Kg on flywheel) x peak revolutions x 11.765 
 
 
FI was calculated as; 
 
 
 FI = Highest APP – Lowest APP / Highest APP x 100 
 
 
Exclusion Criteria; Subjects were excluded if body fat percentage was higher 
than 20% as determined by skinfold assessment, any positive (‘yes’) response on the 
physical activity readiness questionnaire (PAR-Q; Appendix A), responses on the health 
history form (Appendix B), indicative of increased cardiovascular risk for exercise (as 
outlined by ACSM) or lack of adequate sprint training history on the exercise history form 
(Appendix C).  A timeline of the study is presented in Figure 6. 
 
Figure 6. Study Timeline 
 
 
 
 
Exercise Sessions 
 Subjects reported to the lab after an overnight fast. An indwelling IV catheter was 
placed in the arm of the subject so that blood draws could be taken throughout the 
session.  The first blood draw was done 30 minutes prior to exercise.  Exercise began 
with a 6 minute warm-up done at a standardized intensity of 50 watts (W).  After the 
warm-up, each subject completed 4 3-minute exercise bouts at 50% of AMP, separated 
by 6 minutes of active recovery at an intensity of 50 W watts.  This timing and intensity 
was chosen from the pilot study, as it elicited the alterations in blood glucose necessary 
Exc Session 2 
1 Week 1 Week 
Screening Session 
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to test the hypotheses.  Subjects were given water ad libitum, and water intake was not 
recorded.  Blood draws consisted of 5 ml purple top (EDTA-treated) tubes and 5 ml red 
top (blank) tubes taken immediately prior to and immediately after each high intensity 
interval.  The final draws took place 15 minutes and 30 minutes post exercise.  These 
time points were chosen since exercise-induced changes in visfatin have been shown to 
be reduced to baseline levels by 30 minutes post exercise (Jurimae, Ramson et al. 
2009). Finally, in order for some subjects to be able to complete each bout, resistance 
was adjusted.  Total work (in watts) was calculated for each bout to control for any 
difference between exercise sessions.  To further asses work, heart rate was recorded 
at each blood draw. 
 One exercise session included a carbohydrate supplementation.  
Supplementation was given 30 minutes prior to exercise as determined through pilot 
testing.  Supplementation consisted of 236 ml of Gatorade G01 Prime carbohydrate 
solution, as described in the pilot testing session (50g of carbohydrates, 0g of protein, 0g 
of fat; 35mg of potassium, and 110mg of sodium). A timeline of the blood draw protocol 
is diagrammed in Figure 7.    
Blood Processing and Analysis 
 
 EDTA treated tubes were inverted several times after being collected to ensure 
proper mixing. Blood in the EDTA tubes as well as the blank tubes was centrifuged at 
3000 rpm at 4°C for 15 minutes.  Plasma was pipetted into centrifuge tubes and stored 
at -80°C until analysis.  Blood was also collected into capillary tubes prior to exercise, 
after the second session, and after the fourth session.  Hematocrit was assessed by 
centrifuging the capillary tubes for 5 minutes at 10000 RPMs and using a ruler to 
determine the ratio of compacted red blood cells to plasma.   
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Figure 7. Session Timeline. 3-minute exercise bouts are represented by cycles while 
blood draws are represented by asterisks. 
 
 
Insulin resistance was assessed using HOMA-IR, which was calculated as; 
 
 HOMA-IR = Resting BG x Resting insulin/22.5 
 
 
In this equation, resting BG and resting insulin were calculated as the mean 
values of the 0 time point from both sessions, and the 15 minute time point from the 
placebo session. 
Visfatin; Plasma visfatin concentrations were determined via commercially available 
sandwich assay ELISA kit (Adipobiosciences, Santa Clara, CA, USA).  The analysis was 
done at 450nm wavelength using a microplate reader (Biotek Instruments, Winesski, 
VT).  All samples were measured in duplicate and compared to standards.  The mean 
interassay coefficient of variance (CV) was 7.32% and the mean intrassay CV was 
4.05% 
Blood Glucose; Plasma glucose was determined via commercially available assay kit 
(Cayman Chemical, Ann Arbor, MI, USA).  Analysis was done using a microplate reader 
(Biotek Instruments, Winesski, VT) at 515nm wavelength and all samples were 
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measured in duplicate and compared to standards.  The mean interassay CV was 
8.64%, and the mean intrassay CV was 5.49% 
Insulin; Plasma insulin was determined via commercially available assay kit (Mercodia, 
Winston-Salem, NC, USA).  Analysis was done using a microplate reader (Biotek 
Instruments, Winesski, VT) at 450 nm wavelength.  All samples were measured in 
duplicate and compared to standards.  The mean interassay CV was 6.84%, and the 
mean intrassay CV was 3.84%. 
 
Statistical Analysis 
Exercise Variables 
 AMP, HR, and plasma volume were all analyzed using a paired samples t-test. 
Specific Aims #1-2 
Blood glucose, visfatin, and insulin were all analyzed using a 2 (condition: 
supplementation and non-supplementation) x 12 (time point) multivariate analysis of 
variance (MANOVA).  Where a main effect was found, post hoc testing was done using 
least squared differences.  To further analyze the response of the blood variables to 
exercise, a time series analysis was done using autoregressive integrated moving 
average (ARIMA).  Blood variables were compared between groups by determining 
relative area under the curve (AUC), and analyzing AUC with a paired samples t-test.    
Finally, to further assess the effect of exercise on visfatin, exercise data was 
teased apart from non-exercise data and were analyzed using a 2 (pre and post) x 2 
(CHO and placebo) x 4 (exercise bout) MANOVA.  Area under the curve was also 
assessed based on exercise using a 2 (CHO and placebo) x 4 (exercise bout) ANOVA.  
To determine the response of visfatin to exercise, the change in visfatin between time 
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points and from resting values was also assessed using a 2 (condition: placebo and 
carbohydrate by 12 (time point) MANOVA was used. 
Specific Aim #3 
 The relationship between plasma visfatin and body fat were correlated using a 
pearson product-moment correlation coefficient.   
 All data was analyzed using an SPSS statistical package (version 21) with 
statistical significance set at an alpha level of ≤ 0.05. 
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CHAPTER IV 
RESULTS 
 
 
Subjects 
 
  Each subject completed a DXA scan as part of the study. Body composition and 
other subject characteristics are shown in Table 3.  All subjects reported to the lab at the 
same time on both treatment days after an overnight fast.  Prior to exercise, resting 
blood pressure and heart rate were determined.  
 
Table 3. Subject Characteristics (N=10) 
 Mean ± SD 
Age (years) 26.4 ±  5.3 
Height (m) 1.77 ±  0.03 
Weight (kg) 78.78 ± 9.10 
BMI (kg/m2) 24.19 ± 2.82 
Body Fat (%) 13.96 ± 7.28 
Resting SBP (mmHg) 113.5 ± 9.3 
Resting DBP (mmHg) 71.6 ± 8.2 
RHR (bpm) 61.5 ± 7.6 
 
 
 
Diet 
 
 Each subject filled out a 3-day dietary recall (Appendix F).  Subjects were asked 
to try to replicate this diet for the three days prior to the next trial based on the previous 
recall.  Only half the subjects returned both dietary recalls (N = 5).  The macronutrient 
intake of each subject was analyzed from dietary recalls available.  These data are 
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presented in Table 4.  Based on a paired samples t-test, there were no macronutrient 
differences between trials.  Furthermore, all subjects refrained from exercise for 48 
hours prior to both trials, and no subject was taking any prescription or over the counter 
medication including multivitamins. 
 
Table 4. Dietary Record Results 
 
CHO Trial (mean ± 
SD) 
Placebo Trial (mean 
± SD) 
P Value 
Total Kcal 2398 ± 241 2417 ± 303 0.897 
Kcal from 
CHO 
1255.1 ± 172.5 1305.4 ± 198.2 0.749 
Kcal from 
Protein 
667.1 ± 86.3 708.9 ± 70.1 0.871 
Kcal from 
Fat 
544.6 ± 103.1 486.5 ± 189.0 0.782 
 
 
Wingate Test 
 
 Subject workload was determined by a Wingate test on the screening 
day.  Absolute mean power for all subjects was 633.8 W, and mean predicted 
workload for the trials was 317.4 W.  Actual workload results from the 2 trials are 
shown in Table 5.  Workload was adjusted so that every subject could complete 
each three-minute bout of sprint exercise and mean workload decreased slightly 
with each sprint bout. While the actual workload was lower than predicted, there 
was no difference between the two treatments in total workload (CHO mean: 
293.5 W, placebo mean: 292.6 W, p = 0.726) as determined by paired t-tests.  
Paired t-tests were also used to compare each bout between treatment groups. 
Mean workload per trial is shown in Table 5, and mean HR per blood draw is 
shown in Table 6. 
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Table 5. Total Work Done (Watts) 
 CHO Trial (mean ± SD) 
Placebo Trial 
(mean ± SD) 
P Value 
Predicted 317.4 ± 47.26 317.4 ± 47.26 N/A 
Bout 1 303.3 ± 43.98 302.6 ± 41.57 0.787 
Bout 2 294.5 ± 46.28 300.3 ± 49.96 0.339 
Bout 3 290.7 ± 45.90 286.2 ± 50.22 0.613 
Bout 4 285.4 ± 51.39 281.1 ± 54.45 0.416 
 
Table 6. Exercise Heart Rate (bpm) 
Time Point CHO Trial (mean ± SD) Placebo Trial (mean ± 
SD) 
Pre-0 61 ± 13 62 ± 12 
Pre-15 58 ± 7 59 ± 9 
Pre-Bout 1 101 ± 25 91 ± 20 
Post-Bout 1 154 ± 23 159 ± 22 
Pre-Bout 2 117 ± 17 122 ± 11 
Post-Bout 2 160 ± 26 163 ± 29 
Pre-Bout 3 122 ± 21 119 ± 16 
Post-Bout 3 170 ± 17 162 ± 33 
Pre-Bout 4 125 ± 21 128 ± 23 
Post-Bout 4 172 ± 30 169 ± 29 
Post-15 96 ± 15 101 ± 12 
Post-30 84 ± 18 78 ± 11 
 
Plasma Volume 
 To account for changes in plasma volume, hematocrit was determined at the first 
blood draw, halfway through exercise, and after exercise.  These data are shown in 
Table 7.  As shown, a 2 (treatment) x 3 (time point) ANOVA revealed no significant 
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interaction effect or main effect of a carbohydrate supplement on plasma volume 
(p=0.697 and 0.712, respectively).  Within a specific treatment, plasma volume was 
significantly different halfway through exercise compared to pre and post exercise. 
 
Table 7. Hematocrit Changes 
 Supplement (Mean ± SD) Placebo (Mean ± SD) 
Pre (%) 45.98 ± 3.04 44.47 ± 6.02 
Mid (%) 49.36 ± 3.74* 50.17 ± 3.91* 
Post (%) 44.93 ± 4.23 44.11 ± 3.58 
* p < 0.05 compared to pre and post 
 
 
Blood Markers 
 
Visfatin  
 
A 2 (treatment) x 12 (time point) RMANOVA showed no statistically significant 
interaction effect or main effect of exercise or supplement on plasma visfatin (Table 8).  
The pattern of visfatin during the trial is pictured in Figure 8 and mean visfatin values for 
each time point are presented in Table 9. 
 
 
  
 
 
 
 
 
 
 
Table 8. Visfatin RMANOVA Results 
Effect F-value p-value 
Supplement x Time Point 1.860 0.182 
Supplement 2.312 0.163 
Time Point 0.413 0.692 
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Treatments were further compared by analyzing the area under the curve (Figure 
9).  Area under the curve was adjusted to resting value.  Statistical analysis was done 
using a paired t-test and again, no significant difference (p = 0.150) was observed 
between the two treatments.  
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Table 9. Plasma Visfatin (ng/ml) 
 
Time Point 
CHO Supplement  
(mean ± SD) 
Placebo (mean ± SD) 
Pre-0 15.35 ± 14.74 22.66 ± 25.46 
Pre-15 min 15.79 ± 13.64 22.37 ± 23.74 
Pre-Bout 1 16.07 ± 13.73 20.26 ± 20.65 
Post-Bout 1 17.90 ± 19.89 20.14 ± 19.93 
Pre-Bout 2 14.34 ± 12.82 22.23 ± 28.00 
Post-Bout 2 16.09 ± 17.73 23.26 ± 28.85 
Pre-Bout 3 15.87 ± 15.95 21.40 ± 24.78 
Post-Bout 3 15.78 ± 17.30 23.64 ± 30.50 
Pre-Bout 4 16.44 ± 16.17 22.82 ± 27.09 
Post-Bout 4 16.74 ± 20.63 21.83 ± 27.92 
Post-15 min 18.68 ± 18.73 21.60 ± 25.92 
Post-30 min 22.09 ± 23.28 20.09 ± 21.65 
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Autoregressive integrated moving average also showed no statistically significant 
differences between trials.  There was also no significant difference when visfatin was 
assessed based on change between time points. When exercise was teased apart from 
rest and recovery using a 2 x 2 x 4 MANOVA, no statistically significant difference was 
found between trials.  Finally, when AUC was assessed per exercise bout, again, no 
statistically significant difference was observed.  
Blood Glucose 
 A 2 (treatment) x 12 (time point) RMANOVA was used to analyze differences in 
blood glucose (Table 10).  A significant time by treatment interaction effect (p=0.033) 
and a significant main effect for the treatment (p = 0.047) was observed.  The blood 
glucose profile during the trials is shown in Figure 10 and the mean values for blood 
glucose are presented in Table 11.  Since significant interaction and main effects were 
present, post hoc analysis was completed using least squared differences to compare 
time points across treatments and these results are included in Figure 10 and Table 11.  
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Table 11. Blood Glucose (mg/dl) 
 
Time Point 
CHO Supplement  
(mean ± SD) 
Placebo (mean ± 
SD) 
Pre-0 101.81 ± 27.75 95.09 ± 22.06 
Pre-15 min 125.67 ± 30.65 102.73 ± 30.97 
Pre-Bout 1 138.57 ± 30.71+* 98.10 ± 15.23 
Post-Bout 1 125.29 ± 27.30+* 88.62 ± 17.55‡ 
Pre-Bout 2 131.78 ± 28.43+* 92.02 ± 17.60‡ 
Post-Bout 2 113.48 ± 27.33* 96.79 ± 9.62 
Pre-Bout 3 110.96 ± 33.60 112.07 ± 26.16 
Post-Bout 3 99.87 ± 31.99† 101.95 ± 29.07 
Pre-Bout 4 117.78 ± 40.26 118.51 ± 29.95 
Post-Bout 4 109.64 ± 38.32 113.05 ± 39.69 
Post-15 min 125.48 ± 44.75 111.91 ± 39.36 
Post-30 min 126.54 ± 33.42 99.03 42.51 
 
* = p < 0.05 compared to same time point under placebo  
+ = p < 0.05 compared to pre 0  
† = p <0.05 compared to pre 1 
‡ = p < 0.05 compared to pre 4 
 
 
 
 
Table 10. Glucose RMANOVA Results 
Effect F-value p-value 
Supplement x Time Point 2.921 0.033* 
Supplement 5.623 0.047* 
Time Point 1.534 0.226 
*Significant at level of p ≤ 0.05 
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Differences in plasma glucose between treatments were also analyzed by 
determining total area under the curve.  A paired t-test revealed a significantly lower 
area during the placebo treatment when compared to the carbohydrate supplement (p = 
0.050; Figure 11).   
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Insulin 
 A 2 (treatment) x 12 (time point) RMANOVA was used to analyze differences in 
plasma insulin between treatments and time points.  A significant interaction effect (p = 
0.001) as well as significant main effect for treatment (p = 0.045), was found for insulin 
(Table 12).  The plasma insulin response to carbohydrate supplement and a placebo is 
shown in Figure 12 and mean values for insulin are presented in Table 13.  Since 
significant interaction and main effects were present, post hoc analysis was completed 
using least squared differences to compare time points across treatments and these 
results are included in Figure 12 and Table 13.  
 
 
 
 
 
. 
 
Table 13. Plasma Insulin (mU/L) 
 
Time Point 
CHO Supplement  
(mean ± SD) 
Placebo (mean ± SD) 
Pre-0 5.14 ± 1.89 5.80 ± 4.11 
Pre-15 min 18.02 ± 16.84+ 5.84 ± 3.19 
Pre-Bout 1 25.65 ± 13.00+* 8.34 ± 6.88 
Post-Bout 1 25.48 ± 16.65+* 6.78 ± 2.49 
Pre-Bout 2 23.81 ± 13.87+* 8.95 ± 3.84 
Post-Bout 2 23.68 ± 15.31+* 12.35 ± 7.32 
Pre-Bout 3 19.23 ± 12.92+ 13.88 ± 6.64 
Post-Bout 3 14.28 ± 9.30† 10.74 ± 6.98 
Pre-Bout 4 14.49 ± 9.34† 14.64 ± 9.70‡ 
Post-Bout 4 12.47 ± 7.56† 12.78 ± 9.26 
Post-15 min 12.62 ± 8.30† 14.07 ± 11.66‡ 
Post-30 min 13.66 ± 9.45† 15.37 ± 21.76‡ 
Table 12. Insulin RMANOVA Results 
Effect F-value p-value 
Supplement x Time Point 7.218 0.000* 
Supplement 5.434 0.045* 
Time Point 2.780 0.50* 
*Significant at level of p ≤ 0.05 
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* = p < 0.05 compared to same time point during placebo trial 
+ = p < 0.05 compared to pre 0  
† = p <0.05 compared to pre 1 
‡ = p < 0.05 compared to pre 0 and pre 15 
 
 
 
Differences in plasma insulin between treatments were further analyzed by 
determining relative area under the curve.  A paired t-test revealed a significantly lower 
area during the placebo treatment when compared to the carbohydrate supplement (p = 
0.019; Figure 13).   
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Visfatin and Adipose Tissue 
To determine the relationship between adipose tissue and plasma visfatin, 
resting plasma visfatin values were correlated to body fat percentage or truncal adiposity 
(as determined by trunk fat during a DXA scan).  Visfatin and body fat were not 
significantly correlated (p= 0.317, r = 0.2135; data not shown), but truncal fat and plasma 
visfatin were significantly correlated (p = 0.043, r = 0.6162; Figure 14). 
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Visfatin and Blood Glucose 
 To further examine the relationship between blood glucose and plasma visfatin, 
visfatin values were correlated with blood glucose values across all time points (Figure 
15).  Mean values from each time point were correlated with mean glucose values from 
each time point.  No significant correlation was observed between blood glucose and 
plasma visfatin. 
 Additionally, mean visfatin values were correlated with mean plasma insulin 
values (Figure 16).  Mean values from each time pointed were correlated with mean 
insulin values from each time point, and no significant relationship was shown between 
insulin and visfatin.  Finally, resting plasma visfatin was correlated with insulin resistance 
(assessed via HOMA-IR) and no significant correlation was found (r = 0.0047) (data not 
shown). 
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CHAPTER V 
DISCUSSION 
The primary focus of this study was to determine the effects of carbohydrate 
supplementation and high-intensity exercise on plasma visfatin. The major finding of the 
current study is that plasma visfatin did not significantly change after carbohydrate 
supplementation or high-intensity exercise.  To our knowledge, this is the first study to 
examine the effect of high-intensity exercise and a carbohydrate supplement on plasma 
visfatin.   As expected, plasma insulin and glucose were elevated after carbohydrate 
supplementation.  Minor increases were seen in blood glucose and insulin towards the 
end of exercise during the placebo trials.  The glucose and insulin results are similar to 
other studies which have examined plasma insulin and blood glucose after carbohydrate 
supplementation in trained cyclists (Bacurau, Bassit et al. 2002; Lancaster, Jentjens et 
al. 2003).  We hypothesized that high-intensity exercise would increase plasma visfatin, 
and that this increase would be augmented by carbohydrate supplementation.  Based on 
the results, both hypotheses were rejected.   
High-intensity exercise did not illicit a significant change in plasma visfatin in the 
current study.  This is in contrast to some previous studies (Jurimae, Ramson et al. 
2009; Ghanbari-Niaki, Saghebjoo et al. 2010), but supports others (Frydelund-Larsen, 
Akerstrom et al. 2007).  The reason for the lack of statistically significant differences 
found in this study is likely multi-factorial.  Studies that have reported changes in visfatin 
in healthy populations have used different exercise treatments.  Jurimae et al. (2009) 
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found that 120 minutes of rowing done at 88% of heart rate max led to a decrease in 
plasma visfatin 30 minutes after exercise, but not immediately after.  This decrease was 
accompanied by a decrease in insulin immediately after and 30 minutes post exercise.  
Blood glucose did not significantly change.  The authors suggested that this decrease in 
visfatin was partially due to the disruption in metabolic homeostasis elicited by 120 
minutes of moderate intensity exercise.  It is possible that exercise-induced alterations in 
visfatin require some disruption of metabolic homeostasis related to; longer durations of 
exercise, alterations in the fuel mix, or changes in the hormonal milieu that drive 
changes in insulin.  With 120 minutes of submaximal exercise, it is likely that blood 
glucose was utilized as a fuel at some point.  Since glucose never decreased, the 
authors further concluded that visfatin and insulin were both inhibited in an attempt to 
maintain blood glucose. A second possibility is that 120 minutes of exercise enhanced 
glucose uptake through an insulin-independent mechanism which allowed for plasma 
visfatin to decrease since glucose uptake was already enhanced by exercise.  Since 
blood glucose was not altered and glucose uptake was not assessed, this is speculation.   
It is possible that the exercise protocol utilized in the current study was not long enough 
to cause significant inhibition of insulin since insulin was not significantly decreased 
below resting values during or after exercise.  This lack of insulin inhibition may have led 
to the lack of a significant visfatin alteration.  If visfatin is primarily involved in glucose 
homeostasis, then it would be expected to be altered in a manner similar to insulin.  In 
the current study, visfatin did not change in concert with either glucose or insulin in 
response to exercise or carbohydrate supplementation, suggesting it is not acting 
primarily as an insulin-mimetic. 
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Ghanbari-Niaki (2010) et al. found an increase in plasma visfatin after a series of 
35 m treadmill sprints.  Insulin, blood glucose, and HOMA-IR were also elevated 
immediately after the sprint exercise.  The authors concluded that this may be due to the 
transient increase in insulin resistance seen with high-intensity exercise.  High-intensity 
exercise has been shown to cause a transient decrease in insulin sensitivity partially due 
to elevated catecholamines and growth hormone levels (MacDougall, Ward et al. 1977; 
Felsing, Brasel et al. 1992; Zouhal, Vincent et al. 2009).  The authors suggested that 
visfatin is elevated after high intensity exercise in an attempt to enhance glucose uptake 
by the muscle in a state of transient insulin resistance.  The exercise protocol utilized in 
the current study was a lower intensity than used during this previous study.  Seeing as 
no change in insulin sensitivity was seen (as assessed by HOMA-IR), it is likely that the 
intensity utilized was not high enough to elicit a change in insulin sensitivity or a resulting 
change in plasma visfatin.   
Frydelund et al. (2006) found results somewhat similar to the current study.  In 
this study, healthy young men were also used as subjects.  Subjects exercised for 3 
hours at 60% of VO2 max.  Plasma visfatin did not change, but plasma insulin decreased 
with long duration exercise.  Furthermore, they found visfatin mRNA in adipose tissue 
was significantly elevated.  A similar elevation was not seen in visfatin mRNA in skeletal 
muscle.  The authors concluded that visfatin does not play a cellular role regarding 
glucose uptake, but may instead have more of an enzymatic role in adipose tissue 
during exercise.  As previously stated, visfatin has also been referred to as NAMPT for 
its enzymatic action in the NAD-salvage pathway.  During prolonged exercise, visfatin 
mRNA may be increased to catalyze the conversion of nicotinomide to NMN within the 
tissue, resulting in greater NADH concentration and enhanced oxidative 
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phosphorylation.  As mRNA in active muscle was not elevated, this seems less likely to 
be a plausible explanation in this case.  Furthermore, visfatin mRNA was at its highest 
level 1.5 hours after exercise but plasma visfatin was never altered.  These mRNA 
findings may be more indicative of visfatin’s role as a proinflammatory cytokine than its 
enzymatic role.  Since the final blood draw was 90 minutes after exercise, it is possible 
that plasma visfatin was elevated after this as part of an inflammatory response. 
The lack of plasma changes (in the current study as well as the Frydelund et al 
study) suggests that visfatin may be have autocrine actions rather than endocrine 
actions.  Perhaps the reason that plasma visfatin changes have been so varied is that 
any metabolic action of visfatin takes place in an autocrine fashion.  Since multiple 
studies have shown visfatin to enhance glucose uptake in vitro (Fukuhara, Matsuda et 
al. 2005; Xie, Tang et al. 2007), and it is not fully understood what tissues preferentially 
secrete visfatin, any metabolic effect visfatin has may be strictly within a cell without 
being secreted into the blood.  Because it lacks a typical signal sequence for secretion, 
visfatin was originally thought to be only present in plasma due to cell lysis or death (Hug 
and Lodish 2005).  Visfatin has since been shown to be secreted through a non-classical 
pathway (Revollo, Korner et al. 2007).  This same study by Revollo et al (2007) only 
examined visfatin secretion from adipocytes.  The autocrine action of visfatin may 
provide a possible explanation for the lack of significant findings in the current study.  
Visfatin’s enzymatic action in the NAD salvage pathway could partially explain why 
exogenous visfatin has been shown to increase glucose uptake.  Increasing visfatin 
would lead to an increase in available NAD.  It could be speculated that increasing the 
availability of NAD may increase the glycolytic rate within a cell.  As the glycolytic rate is 
increased, glucose uptake would also be increased.  This possible affect on glycolytic 
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rate has not been shown, but it may provide an explanation for why exogenous visfatin 
has been shown to increase glucose uptake.  Furthermore, it may help to explain why 
plasma visfatin responds completely differently in obese populations than it does in 
healthy populations.  
Finally, it is possible that protein expression of visfatin in the muscle or adipose 
tissue was altered by treatment in the current study, but we did not assess either mRNA 
or protein content and therefore, we can’t make conclusive comments about this.  
Furthermore, as Revollo et al (2007) have suggested, visfatin may only be secreted from 
specific cells.  As no study has examined the response of visfatin in human skeletal 
muscle to exercise, its response is unknown.  Further research is needed to determine if 
the exercise-induced visfatin response is largely autocrine. 
The aforementioned studies showed that plasma visfatin can be either increased 
or decreased with exercise.  Based on this limited research, the potential metabolic 
action of visfatin may be more dependent on intensity and substrate utilization than 
anything else.  In the current study, the lack of change in visfatin may be partially due to 
the intensity utilized.  The intensity may have not have been high enough to cause a 
transient insulin resistance and the theorized resulting increase in plasma visfatin.  
Conversely, the decrease in plasma visfatin after 120 minutes of exercise shown in other 
studies (Jurimae, Ramson et al. 2009) may have been due to the duration of exercise 
accomplished and the concomitant decrease in insulin release seen with long-duration 
exercise.  In the current study, subjects exercised for a total of 45 minutes.  To 
summarize, it is possible that the protocol used in the current study may not have been 
long enough to elicit a decrease in plasma visfatin due to a decrease in blood glucose 
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and not intense enough to cause an increase in plasma visfatin due to transient insulin 
resistance. 
Other studies that have shown changes in plasma visfatin have utilized subjects 
where altered insulin function is present, such as type I or type II diabetics, or those who 
are insulin resistant. In addition, most of these studies have used chronic exercise 
training as the treatment.  All of these studies showed decreases in plasma visfatin after 
training (Haider, Pleiner et al. 2006; Choi, Kim et al. 2007; Brema, Hatunic et al. 2008; 
Haus, Solomon et al. 2009).  The overall conclusion drawn from these studies is that 
visfatin may only play a metabolic role when insulin function is already impaired.  With 
exercise training, insulin sensitivity is enhanced, and plasma visfatin may play less of a 
role which could lead to a decrease in plasma levels.  While this conclusion may be 
correct, it cannot be confirmed by the current study as subjects were apparently healthy, 
non-diabetic, trained, and the study was acute.  Furthermore, one study has shown 
visfatin to increase insulin release from the pancreas in rats (Revollo, Korner et al. 
2007).  It could be hypothesized that the effect on pancreatic insulin release may also be 
more robust in obese individuals (similar to other visfatin related effects) compared to 
healthy individuals, but the current study did not assess pancreatic insulin release and 
therefore, we can’t make any conclusions related to the effect of visfatin on the 
pancreas. 
The aforementioned studies showed that plasma visfatin can be either increased 
or decreased with exercise.  Based on this limited research, the potential metabolic 
action of visfatin may be more dependent on intensity and substrate utilization than 
anything else.  In the current study, the lack of change in visfatin may be partially due to 
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the intensity utilized.  The intensity was not high enough to cause a transient insulin 
resistance and the theorized resulting increase in plasma visfatin.  Conversely, the 
decrease in plasma visfatin after 120 minutes of exercise shown in other studies 
(Jurimae, Ramson et al. 2009) may have been due to the duration of exercise 
accomplished and the concomitant decrease in insulin release seen with long-duration 
exercise.  In the current study, subjects exercised for a total of 45 minutes.  To 
summarize, it is possible that the protocol used in the current study may not have been 
long enough to elicit a decrease in plasma visfatin due to a decrease in blood glucose 
and not intense enough to cause an increase in plasma visfatin due to transient insulin 
resistance. 
The second aim of this study was to determine the effect of carbohydrate 
supplementation on plasma visfatin.  Ingestion of a glucose supplement prior to exercise 
had no effect on plasma visfatin, or on its response to exercise.  While research is 
minimal and varied regarding the response of visfatin to carbohydrate intake 
(Marcinkowska, Lewandowski et al. 2007; Zhaoxia, Ying et al. 2012), no study has 
examined the effect of glucose intake on plasma visfatin in healthy individuals.  In the 
current study, glucose ingestion led to a significant increase in both plasma insulin and 
glucose with no change in plasma visfatin.  According to these data, the second 
hypothesis is rejected.  Again, if visfatin plays a role in blood glucose homeostasis, then 
it would be expected to be altered with carbohydrate ingestion. 
Carbohydrate supplementation caused an elevation in plasma glucose and 
insulin which lasted through the first half of exercise when compared to the placebo trial.  
It can be assumed that the carbohydrate supplement caused an alteration in 
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macronutrient fuel utilization during exercise, although we did not assess changes in R 
values during exercise.  The increased availability of glucose likely lead to an increased 
reliance on blood glucose as a fuel for exercise (as blood glucose was elevated prior to 
exercise during the CHO trial) (Pirnay, Lacroix et al. 1977; Jenkins, Hutchins et al. 
1994).  Blood glucose returned to baseline halfway through exercise.  This clearing of 
blood glucose was likely due to an increase in glucose uptake by active muscles during 
exercise (through both insulin-dependent and independent mechanisms). This glucose 
response is typical of fit individuals after a carbohydrate supplement prior to exercise 
(Jeukendrup, Brouns et al. 1997; Pedersen, Lessard et al. 2008).  As plasma visfatin did 
not change, it can be concluded that plasma visfatin did not facilitate the clearing of 
blood glucose and did not improve glucose uptake in the current study.    
The initial increase in insulin in the CHO trial is due to the elevated blood glucose 
after carbohydrate ingestion.  The continued elevation in insulin may be due to an 
increase in transient insulin resistance in response to elevated growth hormone and  
catecholamines seen with high-intensity exercise (MacDougall, Ward et al. 1977; 
Felsing, Brasel et al. 1992; Jurimae, Ramson et al. 2009; Ghanbari-Niaki, Saghebjoo et 
al. 2010).  These previous studies have shown blood glucose and insulin to be elevated 
towards the end of high-intensity exercise in healthy populations.  While not statistically 
significant, blood glucose did slightly increase 30 minutes after exercise.  This may be 
due to an increase in gluconeogenesis and glucose output from the liver as a result of 
elevated catecholamines and an attempt to replenish muscle glycogen.   
To summarize, visfatin has been shown to have three actions; enzymatic action 
in the NAD-salvage pathway, inflammatory effects as a pre-B cell colony enhancing 
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factor, and its role in insulin signaling/glucose homeostasis.  The lack of significant 
findings in the current study may be partially explained by visfatin’s enzymatic action.  
Visfatin catalyzes the conversion of nicotinamide to nicotinic acid mononucleotide (NMN) 
in the NAD salvage pathway (Figure 1).  During exercise, NAD turnover rate is increased 
due to an increase in glycolytic rate and concomitant increase in NADH production.  
Visfatin may be enhanced within the muscle in order to catalyze this increase in NAD 
synthesis.  This is supported by previous research which has shown visfatin to increase 
NAD production and the activity of sirtuin proteins (Revollo, Grimm et al. 2004).  Sirtuin 
proteins respond to alterations in energy balance and NAD turnover rate.  The enzymatic 
activity of visfatin may also explain the results of previous studies which have shown 
exogenous visfatin to enhance glucose uptake in vivo and in vitro (Fukuhara, Matsuda et 
al. 2005; Xie, Tang et al. 2007; Song, Lee et al. 2008).  An increase in the availability of 
visfatin may increase NAD synthesis which would increase the glycolytic rate.  This 
increase in the glycolytic rate may increase the breakdown of cellular glycogen and 
increase glucose uptake by mechanisms independent of insulin.  The timeline for this is 
still unclear. 
The elevation in visfatin seen with type II diabetes and obesity may be due to 
visfatin’s proinflammatory action.  Visfatin was originally discovered as an inflammatory 
cytokine expressed in the presence of pokeweed mitogen (Samal, Sun et al. 1994).  
Additionally, it has been suggested to influence the NF-kB pathway (Tilg and Moschen 
2008).  Its potential interaction with the NF-kB pathway is another characteristic it shares 
with the sirtuin proteins.  Visfatin has been shown to be elevated in states of obesity-
induced inflammation as well as other states of inflammation along with the sirtuin 
proteins and NF-kB (Alexandraki, Piperi et al. 2006; Tilg and Moschen 2008; Li, Yang et 
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al. 2009).  The interaction of these substances is not fully understood, but it is possible 
that the elevated visfatin levels seen in type II diabetics and obese individuals may 
partially be a result of chronic inflammation and not just due to an alteration in glucose 
homeostasis or insulin sensitivity.   
In addition to the lack of a significant change with treatment, plasma visfatin 
varied greatly between subjects in the current study.  Resting plasma visfatin levels 
ranged from 3.67 ng/ml to 84.83 ng/ml.  This variation is consistent with other studies 
which have reported mean resting visfatin values from 6 ng/ml to 55.8 ng/ml in healthy 
individuals and values up to 142 ng/ml in obese individuals (Ghanbari-Niaki, Saghebjoo 
et al. 2010; Jorge, de Oliveira et al. 2011; Jurimae, Gruodyte et al. 2011).  The reason 
for this large variability in resting values is not fully understood.  In the current study, 
plasma visfatin values were not significantly correlated to blood glucose, insulin or body 
fat percentage, but were significantly correlated with truncal adiposity.  The third specific 
aim of this study was to determine the relationship between truncal fat and plasma 
visfatin.  We hypothesized (and confirmed) that plasma visfatin would be positively 
correlated with truncal fat in healthy males.  Previous studies have shown there to be a 
positive relationship between truncal fat and abdominal fat (Parikh, Joshi et al. 2007).  
This relationship has between abdominal fat and plasma visfatin has been shown in 
obese populations in previous studies, but to our knowledge, this is the first study to 
establish such a correlation in healthy non-obese individuals, and may partially explain 
the large variation in visfatin levels at rest.  The variation in the current study is likely due 
to this relation with truncal fat and not likely due to variations in insulin sensitivity 
between subjects as suggested in previous research (Ghanbari-Niaki, Saghebjoo et al. 
2010; Jurimae, Gruodyte et al. 2011), considering all subjects were apparently healthy, 
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and plasma visfatin was not correlated to blood glucose, insulin, or insulin resistance 
(HOMA-IR) at any time point.   
All subjects filled out health-history and physical activity questionnaires (appendix 
A and B).  One subject reported having a family history of type II diabetes.  Fasting blood 
glucose levels for this subject were elevated (mean of 130 mg/dl) compared to other 
subjects.  One other subject had an elevated mean fasting glucose value (107 mg /dl) 
without reporting any family history of T2D.  Fasting visfatin levels of both subjects were 
less than one standard deviation from the group mean.  Furthermore, after statistical 
analysis of insulin and visfatin with resting blood glucose as a cofactor, the results did 
not differ from what has been presented.  
Ten subjects were tested in the study as determined by a power analysis done 
prior to the study and based on previous published data. The observed power of the 
main effect (visfatin response) in the current study was 0.812.  While the desired power 
of 0.80 was reached, more subjects may have increased the power and the likelihood of 
significant results.   
 The current study was an attempt to clarify the role that visfatin has regarding 
glucose metabolism.  As much control was employed as possible to eliminate 
confounding variables from the current study.  There were, however, some limitations.  
First, training status varied from subject to subject.  Subjects were eliminated if they did 
not train at a high-intensity at least twice per week and have a body fat percentage 
below 20 (assessed via 7-site skinfold).  While that did limit the subject pool to trained 
individuals, some subjects were more highly trained than others.  Another limitation is 
the mode with which most subjects were trained.  When possible, subjects who cycled 
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regularly were used, but some subjects (n = 4) had very little experience cycling.  As the 
mode of exercise was cycling, inexperienced subjects may have been somewhat limited 
by their cycling ability.  Furthermore, some subjects (n = 2) had elevated mean fasted 
blood glucose.  We expected active individuals to have normal fasting blood glucose, so 
we did not use elevated fasting blood glucose as one of the exclusion criteria, but we 
recognize that this may have influenced our results.  Also, carbohydrate 
supplementation was not based on body weight.  There was not a vast difference in 
body weight between subjects (78.78 kg ± 9.10) or grams of carbohydrate per kg of body 
weight (641 mg ± 68 mg) and plasma visfatin was not correlated to body weight. The 
dosage of carbohydrate was based on a previous study which found 50g of 
carbohydrates elevated blood glucose in healthy individuals (Kraemer, Francois et al. 
2011).  While supplementation was not based on body weight, blood glucose was 
significantly increased beyond resting levels in all individuals after supplementation.  As 
the purpose of this study was to assess plasma visfatin changes in response to blood 
glucose changes, the carbohydrate supplement used should have been an adequate 
stimulus.  Finally, due to budget constraints, a true control (no exercise & no 
supplementation) was not used in this study.  The ideal study design would have used 
more trials to test various combinations [no exercise & no supplementation; no exercise 
& CHO supplementation; no exercise & placebo; exercise & CHO supplementation and 
exercise & placebo]. 
 Future research is needed to determine the extent to which visfatin acts on 
glucose homeostasis.  There are still very few studies which examine plasma visfatin in 
healthy individuals.  Another possible direction that could be used to ascertain the role of 
visfatin is to complete glucose or insulin clamping studies.  These types of studies could 
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help to determine visfatin’s action in states of altered insulin action and would provide 
another method to manipulate blood glucose.  Also, repeating this study in a 
hyperglycemic population may help to further determine the action of visfatin on blood 
glucose.  Previous studies using hyperglycemic individuals as subjects have shown 
significant roles for visfatin (refs), the current results could be compared to 
hyperglycemic individuals to determine how visfatin acts when blood glucose is 
manipulated through exercise and supplementation in states of decreased insulin 
sensitivity.  Furthermore, multiple studies (including this one) have found resting visfatin 
levels to be greatly varied between individuals.  The reason for this variation can only be 
partially explained by truncal adiposity and requires further investigation.  Very little is 
known regarding the release or mechanism of action of visfatin, or its interaction with 
other hormones and compounds in the majority of tissues.    Further research is needed 
to determine which of visfatin’s actions is primary and if its actions vary between tissues.   
 Finally, visfatin’s potential autocrine actions have not been investigated.  The 
present study was an attempt to determine the response of plasma visfatin to alterations 
in blood glucose.  No relationship between the two was found.  Previous studies which 
have investigated the response of plasma visfatin to exercise or carbohydrate ingestion 
have been minimal and the results of been varied.  In order to fully understand the role 
visfatin may play in metabolism, it is important to assess its action within the cell. 
 In summary, this study showed that high-intensity intermittent exercise had no 
effect on the plasma visfatin levels of trained healthy males.  Furthermore, carbohydrate 
supplementation had no effect on resting or exercise plasma visfatin levels.  No 
relationship was shown between plasma visfatin and blood glucose, plasma insulin, or 
71 
 
body fat percentage.  A significant correlation, however, was found between plasma 
visfatin and total truncal fat.   
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APPENDIX A 
PHYSICAL ACTIVITY READINESS QUESTIONNAIRE (PAR-Q) 
Subject:        
ID:          
Please circle Yes or No for each question.   If Yes please explain. 
Health History 
Do you have any musculoskeletal illnesses or injuries that would restrict your 
participation in a submaximal exercise bout (as performed on a treadmill)?   
   
        YES                               NO                            
If yes, please describe.          
              
Have you ever been diagnosed with cardiovascular disorders (heart problems, high blood 
pressure, high cholesterol, abnormal heart rhythms, etc.)?   
Family History     YES                               NO  
Cigarette smoking      YES                               NO 
Hypertension      YES                               NO 
Hypercholesterolemia     YES                               NO 
Impaired fasting glucose    YES                               NO 
Obesity      YES                               NO    
Sedentary lifestyle     YES                               NO   
High serum LDL cholesterol    YES                               NO 
If yes, please describe.          
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Have you ever been diagnosed with any metabolic disorders (diabetes, etc.)? 
        YES                               NO                            
If yes, please describe.          
              
 
Could you currently be pregnant?   YES                             NO    
 
Please list any major illnesses, hospitalizations, or surgical procedures within the last two 
years. 
              
              
 
Drug/Supplement Usage 
 
Are you a current smoker or user of tobacco? YES                             NO 
Have you ever smoked in the past?                           YES                             NO    
If yes, please describe history.         
             
Are you currently taking any medication(s)?  YES                             NO                                
If yes, please list name of medication(s), reason for usage and length of administration. 
              
              
              
              
Are you currently taking any nutritional/vitamin supplements?   
        YES                             NO     
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If yes, please list name of supplement, reason for usage and length of administration. 
              
              
              
              
Do you have any joint pain?   YES  NO 
 Have you experienced shortness of breath at rest or during exercise?  YES NO 
              
              
              
Have you had a large change in weight over the past 3 months?    YES         NO   
              
              
              
Have you seen a change in your health status in the past 3 months?   YES        NO   
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APPENDIX B 
AHA/ACSM HEALTH/FITNESS FACILITY PRE-SCREENING 
Assess your health needs by marking all true statements. 
 
History 
You have had: 
__ a heart attack 
__ heart surgery 
__ cardiac catheterization 
__ coronary angioplasty (PTCA) 
__ pacemaker/implantable cardiac defibrillator/rhythm disturbance 
__ heart valve disease 
__ heart failure 
__ heart transplantation 
__ congenital heart disease 
 
Symptoms 
__ You experience chest pain with exertion. 
__ You experience unreasonable breathlessness. 
__ You experience dizziness, fainting, blackouts. 
__ You take heart medications. 
 
Other health issues 
__ You have musculoskeletal problems. 
__ You take prescription medication(s). 
__ You may be pregnant. 
 
If you marked any of the statements in this section, consult your healthcare provider 
before engaging in exercise. You may need to use a facility with a medically 
qualified staff. 
________________________________________________________________________
______ 
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Cardiovascular Risk Factors 
__ You are a man older than 45 years. 
__ You are a woman older than 55 years. 
__ You smoke. 
__ Your blood pressure is > 140/90. 
__ You take blood pressure medication. 
__ Your blood cholesterol level is > 240 mg/dl. 
__ You have a close blood relative who had a heart attack before age 55 (father or 
brother) or age 65 (mother or sister). 
__ You are physically inactive (ie, you get < 30 minutes of physical activity on at least 3 
days per week. 
 
 
If you marked 2 or more of the statements in this section, consult your healthcare 
provider before engaging in exercise. You might benefit by using a facility with a 
professionally qualified exercise staff to guide your exercise program. 
________________________________________________________________________
______ 
 
__ None of the above is true. 
 
You should be able to exercise safely without consulting your healthcare provider in 
almost any facility that meets your exercise program needs. 
________________________________________________________________________
______ 
 
Please print, complete and bring this questionnaire to your physician if you have any 
further questions. 
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APPENDIX C 
FITNESS ACTIVITY 
 
 
Please describe your current participation in the following types of exercise: 
 
1. Aerobic (aerobic classes, walking, jogging, stair climbing, cycling, etc.) 
Frequency (# of days per week):      
Duration (time spent per session on avg.):    minutes 
Intensity (difficulty level):  light    somewhat hard hard     very hard 
If you know your HR responses please list it here. _____________________ 
             
 
How long have you been participating in aerobic activity as described above? 
Less than three months 3-6 months 6-12 months      greater than 12 months 
Type of activity:___________________________ 
Additional comments:          
             
 
2. Anaerobic (weight training, sprinting, etc.) 
Frequency (# of days per week):     
Duration (time spent per session):    minutes 
Intensity (difficulty level):  light    somewhat hard hard     very hard 
 
How long have you been participating in anaerobic activity as described above? 
Less than three months 3-6 months 6-12 months      greater than 12 months 
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Type of activity: ____________________________ 
Additional comments:          
             
 
 
3. Organized or Recreational sports or activities  
 
Type of sport(s):          
           
Frequency (# of days per week):     
Duration (time spent per session):    minutes 
Intensity (difficulty level):  light    somewhat hard hard     very hard 
 
How long have you been participating in sports activity as described above? 
Less than three months 3-6 months 6-12 months      greater than 12 months 
Additional comments:          
             
 
 
